AM580	O
,	O
a	O
stable	O
benzoic	O
derivative	O
of	O
retinoic	O
acid	O
,	O
has	O
powerful	O
and	O
selective	O
cyto-differentiating	O
effects	O
on	O
acute	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

All-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
successfully	O
used	O
in	O
the	O
cyto-differentiating	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

Paradoxically	O
,	O
APL	B-cell_line
cells	I-cell_line
express	O
PML-RAR	B-protein
,	O
an	O
aberrant	O
form	O
of	O
the	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
type	I-protein
alpha	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
derived	O
from	O
the	O
leukemia-specific	B-DNA
t	I-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
chromosomal	I-DNA
translocation	I-DNA
.	O

We	O
show	O
here	O
that	O
AM580	O
,	O
a	O
stable	O
retinobenzoic	O
derivative	O
originally	O
synthesized	O
as	O
a	O
RAR	B-protein
alpha	I-protein
agonist	O
,	O
is	O
a	O
powerful	O
inducer	O
of	O
granulocytic	O
maturation	O
in	O
NB4	B-cell_line
,	O
an	O
APL-derived	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
and	O
in	O
freshly	B-cell_type
isolated	I-cell_type
APL	I-cell_type
blasts	I-cell_type
.	O

After	O
treatment	O
of	O
APL	B-cell_line
cells	I-cell_line
with	O
AM580	O
either	O
alone	O
or	O
in	O
combination	O
with	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
,	O
the	O
compound	O
induces	O
granulocytic	O
maturation	O
,	O
as	O
assessed	O
by	O
determination	O
of	O
the	O
levels	O
of	O
leukocyte	B-RNA
alkaline	I-RNA
phosphatase	I-RNA
,	I-RNA
CD11b	I-RNA
,	I-RNA
CD33	I-RNA
,	I-RNA
and	I-RNA
G-CSF	I-RNA
receptor	I-RNA
mRNA	I-RNA
,	O
at	O
concentrations	O
that	O
are	O
10-	O
to	O
100-fold	O
lower	O
than	O
those	O
of	O
ATRA	O
necessary	O
to	O
produce	O
similar	O
effects	O
.	O

By	O
contrast	O
,	O
AM580	O
is	O
not	O
effective	O
as	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
these	O
differentiation	B-protein
markers	I-protein
in	O
the	O
HL-60	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
in	O
freshly	B-cell_type
isolated	I-cell_type
granulocytes	I-cell_type
obtained	O
from	O
the	O
peripheral	O
blood	O
of	O
chronic	O
myelogenous	O
leukemia	O
patients	O
during	O
the	O
stable	O
phase	O
of	O
the	O
disease	O
.	O

In	O
NB4	B-cell_line
cells	I-cell_line
,	O
two	O
other	O
synthetic	O
nonselective	O
RAR	O
ligands	O
are	O
capable	O
of	O
inducing	O
LAP	B-protein
as	O
much	O
as	O
AM580	O
,	O
whereas	O
RAR	O
beta-	O
or	O
RAR	O
gamma-specific	O
ligands	O
are	O
totally	O
ineffective	O
.	O

These	O
results	O
show	O
that	O
AM580	O
is	O
more	O
powerful	O
than	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
differentiation	O
antigens	O
only	O
in	O
cells	O
in	O
which	O
PML-RAR	B-protein
is	O
present	O
.	O

Binding	O
experiments	O
,	O
using	O
COS-7	B-cell_line
cells	I-cell_line
transiently	O
transfected	O
with	O
PML-RAR	B-protein
and	O
the	O
normal	O
RAR	B-protein
alpha	I-protein
,	O
show	O
that	O
AM580	O
has	O
a	O
lower	O
affinity	O
than	O
ATRA	O
for	O
both	O
receptors	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
PML-RAR	B-protein
,	O
the	O
synthetic	O
retinoid	O
is	O
a	O
much	O
better	O
transactivator	O
of	O
retinoic	B-DNA
acid-responsive	I-DNA
element-containing	I-DNA
promoters	I-DNA
than	O
the	O
natural	O
retinoid	O
,	O
whereas	O
,	O
in	O
the	O
presence	O
of	O
RAR	B-protein
alpha	I-protein
,	O
AM580	O
and	O
ATRA	O
have	O
similar	O
activity	O
.	O

This	O
may	O
explain	O
the	O
strong	O
cyto-differentiating	O
potential	O
of	O
AM580	O
in	O
PML-RAR-containing	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

AM5S80	NULL
,	NULL
a	NULL
Stable	NULL
Benzoic	NULL
Derivative	NULL
of	NULL
Retinoic	NULL
Acid	NULL
,	NULL
Has	NULL
Powerful	NULL
and	NULL
Selective	NULL
Cyto-Differentiating	NULL
Effects	NULL
on	NULL
Acute	NULL
Promyelocytic	NULL
Leukemia	NULL
Cells	NULL
By	NULL
Maurizio	NULL
Gianni	NULL
,	NULL
Marco	NULL
Li	NULL
Calzi	NULL
,	NULL
Mineko	NULL
Terao	NULL
,	NULL
Giovanna	NULL
Guiso	NULL
,	NULL
Silvio	NULL
Caccia	NULL
,	NULL
Tiziano	NULL
Barbui	NULL
,	NULL
Alessandro	NULL
Rambaldi	NULL
,	NULL
and	NULL
Enrico	NULL
Garattini	NULL
All-trans	NULL
retinoic	NULL
acid	NULL
(	NULL
ATRA	NULL
)	NULL
is	NULL
successfully	NULL
used	NULL
in	NULL
the	NULL
cyto-differentiating	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
.	NULL

Paradoxically	NULL
,	NULL
APL	NULL
cells	NULL
express	NULL
PML-RAR	NULL
,	NULL
an	NULL
aberrant	NULL
form	NULL
of	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
type	NULL
a	NULL
(	NULL
RARa	NULL
)	NULL
derived	NULL
from	NULL
the	NULL
leukemia-specific	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
chromosomal	NULL
translocation	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
AM580	NULL
,	NULL
a	NULL
stable	NULL
retinobenzoic	NULL
derivative	NULL
originally	NULL
synthesized	NULL
as	NULL
a	NULL
RARa	NULL
agonist	NULL
,	NULL
is	NULL
a	NULL
powerful	NULL
inducer	NULL
of	NULL
granulocytic	NULL
maturation	NULL
in	NULL
NB4	NULL
,	NULL
an	NULL
APL-derived	NULL
cell	NULL
line	NULL
,	NULL
and	NULL
in	NULL
freshly	NULL
isolated	NULL
APL	NULL
blasts	NULL
.	NULL

After	NULL
treatment	NULL
of	NULL
APL	NULL
cells	NULL
with	NULL
AM580	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
G-CSF	NULL
)	NULL
,	NULL
the	NULL
compound	NULL
induces	NULL
granulocytic	NULL
maturation	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
determination	NULL
of	NULL
the	NULL
levels	NULL
of	NULL
leukocyte	NULL
alkaline	NULL
phosphatase	NULL
,	NULL
CD11b	NULL
,	NULL
CD33	NULL
,	NULL
and	NULL
G-CSF	NULL
receptor	NULL
mRNA	NULL
,	NULL
at	NULL
concentrations	NULL
that	NULL
are	NULL
10-	NULL
to	NULL
100-fold	NULL
lower	NULL
than	NULL
those	NULL
of	NULL
ATRA	NULL
necessary	NULL
to	NULL
produce	NULL
similar	NULL
effects	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
AM5S80	NULL
is	NULL
not	NULL
so	NULL
effective	NULL
as	NULL
ATRA	NULL
in	NULL
modulating	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
differentiation	NULL
markers	NULL
in	NULL
the	NULL
HL-60	NULL
cell	NULL
line	NULL
and	NULL
in	NULL
freshly	NULL
isolated	NULL
HE	NULL
CYTO-DIFFERENTIATING	NULL
agent	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
(	NULL
ATRA	NULL
)	NULL
is	NULL
successfully	NULL
used	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
;	NULL
M3	NULL
in	NULL
the	NULL
French-American-British	NULL
[	NULL
FAB	NULL
]	NULL
classification	NULL
)	NULL
..	NULL
``	NULL
In	NULL
this	NULL
type	NULL
of	NULL
dis-ease	NULL
,	NULL
ATRA	NULL
circumvents	NULL
the	NULL
differentiation	NULL
block	NULL
of	NULL
the	NULL
leukemic	NULL
blasts	NULL
,	NULL
causing	NULL
them	NULL
to	NULL
mature	NULL
from	NULL
the	NULL
promyelo-cyte	NULL
stage	NULL
along	NULL
the	NULL
granulocytic	NULL
pathway	NULL
.	NULL
``	NULL

The	NULL
exquisite	NULL
sensitivity	NULL
of	NULL
APL	NULL
blasts	NULL
to	NULL
the	NULL
cyto-differentiating	NULL
action	NULL
of	NULL
ATRA	NULL
is	NULL
paradoxical	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
typical	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
chromosomal	NULL
translocation	NULL
,	NULL
APL	NULL
cells	NULL
express	NULL
PML-RAR	NULL
,	NULL
a	NULL
functionally	NULL
altered	NULL
form	NULL
of	NULL
the	NULL
nuclear	NULL
retinoic	NULL
acid	NULL
receptor	NULL
known	NULL
as	NULL
RARa.5°	NULL
ATRA-dependent	NULL
granulocytic	NULL
differentiation	NULL
is	NULL
reproducible	NULL
on	NULL
cultures	NULL
of	NULL
From	NULL
the	NULL
Molecular	NULL
Biology	NULL
Unit	NULL
,	NULL
Centro	NULL
Catullo	NULL
e	NULL
Daniela	NULL
Bor-gomainerio	NULL
and	NULL
the	NULL
Laboratory	NULL
of	NULL
Drug	NULL
Metabolism	NULL
,	NULL
Istituto	NULL
di	NULL
Ricerche	NULL
Farmacologiche	NULL
``	NULL
Mario	NULL
Negri	NULL
``	NULL
,	NULL
Milano	NULL
;	NULL
the	NULL
Division	NULL
of	NULL
Hematology	NULL
,	NULL
Ospedali	NULL
Riuniti	NULL
di	NULL
Bergamo	NULL
,	NULL
Largo	NULL
Barozzi	NULL
,	NULL
Bergamo	NULL
;	NULL
and	NULL
the	NULL
Istituto	NULL
di	NULL
Ricerche	NULL
Farmacologiche	NULL
``	NULL
Mario	NULL
Negri	NULL
``	NULL
sede	NULL
di	NULL
Bergamo	NULL
,	NULL
Bergamo	NULL
,	NULL
Italy	NULL
.	NULL

Submitted	NULL
June	NULL
14	NULL
,	NULL
1995	NULL
;	NULL
accepted	NULL
September	NULL
21	NULL
,	NULL
1995	NULL
.	NULL

Supported	NULL
in	NULL
part	NULL
by	NULL
Grants	NULL
from	NULL
the	NULL
Consiglio	NULL
Nazionale	NULL
delle	NULL
Ricerche	NULL
(	NULL
CNR	NULL
)	NULL
,	NULL
Progetto	NULL
Finalizzato	NULL
``	NULL
Ingegneria	NULL
Genetica	NULL
``	NULL
'	NULL
,	NULL
Progetto	NULL
Finalizzato	NULL
``	NULL
Biotecnologie	NULL
e	NULL
and	NULL
from	NULL
the	NULL
Associazione	NULL
per	NULL
la	NULL
Ricerca	NULL
contro	NULL
il	NULL
Cancro	NULL
(	NULL
AIRC	NULL
)	NULL
.	NULL

The	NULL
precious	NULL
financial	NULL
contribution	NULL
of	NULL
the	NULL
Associazione	NULL
Paolo	NULL
Belli	NULL
,	NULL
Lotta	NULL
alla	NULL
Leucemia	NULL
to	NULL
A.R	NULL
.	NULL

is	NULL
also	NULL
acknowledged	NULL
.	NULL

M.L.C	NULL
.	NULL

is	NULL
a	NULL
recipient	NULL
of	NULL
a	NULL
fellowship	NULL
from	NULL
``	NULL
La	NULL
via	NULL
di	NULL
Natale	NULL
``	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Enrico	NULL
Garattini	NULL
,	NULL
MD	NULL
,	NULL
Molecular	NULL
Biology	NULL
Unit	NULL
,	NULL
Centro	NULL
Catullo	NULL
e	NULL
Daniela	NULL
Borgomainerio	NULL
,	NULL
Istituto	NULL
di	NULL
Ricerche	NULL
Farmacologiche	NULL
``	NULL
Mario	NULL
Negri	NULL
``	NULL
,	NULL
via	NULL
Eritrea	NULL
,	NULL
62	NULL
.	NULL

20157	NULL
Milano	NULL
,	NULL
Italy	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-497	NULL
1/96/8704-0028	NULL
$	NULL
3.00/0	NULL
1520	NULL
granulocytes	NULL
obtained	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
patients	NULL
during	NULL
the	NULL
stable	NULL
phase	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

In	NULL
NB4	NULL
cells	NULL
,	NULL
two	NULL
other	NULL
synthetic	NULL
nonselective	NULL
RAR	NULL
ligands	NULL
are	NULL
capable	NULL
of	NULL
inducing	NULL
LAP	NULL
as	NULL
much	NULL
as	NULL
AMS580	NULL
,	NULL
whereas	NULL
or	NULL
RARy-specific	NULL
ligands	NULL
are	NULL
totally	NULL
ineffective	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
AM580	NULL
is	NULL
more	NULL
powerful	NULL
than	NULL
ATRA	NULL
in	NULL
modulating	NULL
the	NULL
expression	NULL
of	NULL
differentiation	NULL
antigens	NULL
only	NULL
in	NULL
cells	NULL
in	NULL
which	NULL
PML-RAR	NULL
is	NULL
present	NULL
.	NULL

Binding	NULL
experiments	NULL
,	NULL
using	NULL
COS-7	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
PML-RAR	NULL
and	NULL
the	NULL
normal	NULL
RARa	NULL
,	NULL
show	NULL
that	NULL
AM580	NULL
has	NULL
a	NULL
lower	NULL
affinity	NULL
than	NULL
ATRA	NULL
for	NULL
both	NULL
receptors	NULL
.	NULL

However	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PML-RAR	NULL
,	NULL
the	NULL
synthetic	NULL
retinoid	NULL
is	NULL
a	NULL
much	NULL
better	NULL
transactivator	NULL
of	NULL
retinoic	NULL
acid-responsive	NULL
element-con-taining	NULL
promoters	NULL
than	NULL
the	NULL
natural	NULL
retinoid	NULL
,	NULL
whereas	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RARa	NULL
,	NULL
AMS8O0	NULL
and	NULL
ATRA	NULL
have	NULL
similar	NULL
activity	NULL
.	NULL

This	NULL
may	NULL
explain	NULL
the	NULL
strong	NULL
cyto-differentiating	NULL
potential	NULL
of	NULL
AM58O0	NULL
in	NULL
PML-RAR-containing	NULL
leukemic	NULL
cells	NULL
.	NULL

©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

freshly	NULL
isolated	NULL
APL	NULL
blasts	NULL
as	NULL
well	NULL
as	NULL
on	NULL
cultures	NULL
of	NULL
the	NULL
APL-derived	NULL
NB4	NULL
``	NULL
and	NULL
HL-60	NULL
``	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
basal	NULL
conditions	NULL
,	NULL
APL	NULL
cells	NULL
express	NULL
PML-RAR	NULL
,	NULL
RARa	NULL
,	NULL
and	NULL
the	NULL
retinoic	NULL
acid	NULL
related	NULL
receptors	NULL
known	NULL
as	NULL
RXRs	NULL
,	NULL
``	NULL
whereas	NULL
expression	NULL
of	NULL
RAR	NULL
and	NULL
RARy	NULL
is	NULL
not	NULL
observed	NULL
.	NULL
``	NULL

ATRA-induced	NULL
granulocytic	NULL
differentiation	NULL
leads	NULL
to	NULL
the	NULL
appearance	NULL
of	NULL
mRNAs	NULL
.	NULL
``	NULL

Because	NULL
ATRA	NULL
does	NULL
not	NULL
show	NULL
any	NULL
selectivity	NULL
for	NULL
the	NULL
RAR	NULL
subtypes	NULL
``	NULL
and	NULL
it	NULL
can	NULL
interact	NULL
with	NULL
RXRs	NULL
via	NULL
isomerization	NULL
to	NULL
9-cis	NULL
retinoic	NULL
acid	NULL
(	NULL
9-cis	NULL
RA	NULL
)	NULL
,	NULL
it	NULL
is	NULL
entirely	NULL
possible	NULL
that	NULL
activation	NULL
of	NULL
any	NULL
one	NULL
of	NULL
these	NULL
receptors	NULL
may	NULL
underlie	NULL
the	NULL
differentiation	NULL
process	NULL
.	NULL

ATRA-dependent	NULL
maturation	NULL
of	NULL
APL	NULL
cells	NULL
is	NULL
incomplete	NULL
and	NULL
can	NULL
be	NULL
enhanced	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
other	NULL
cyto-differentiating	NULL
agents	NULL
,	NULL
such	NULL
as	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
G-CSF	NULL
)	NULL
``	NULL
and	NULL
cell-permeable	NULL
cAMP	NULL
analogs	NULL
.	NULL

'*	NULL
``	NULL
'	NULL
With	NULL
respect	NULL
to	NULL
this	NULL
,	NULL
we	NULL
recently	NULL
showed	NULL
that	NULL
leukocyte	NULL
alkaline	NULL
phosphatase	NULL
(	NULL
LAP	NULL
)	NULL
,	NULL
a	NULL
specific	NULL
and	NULL
restrictive	NULL
marker	NULL
for	NULL
the	NULL
postmi-totic	NULL
granulocyte	NULL
,	NULL
``	NULL
is	NULL
not	NULL
expressed	NULL
at	NULL
significant	NULL
levels	NULL
in	NULL
APL	NULL
blasts	NULL
on	NULL
treatment	NULL
with	NULL
ATRA	NULL
alone	NULL
.	NULL

However	NULL
,	NULL
incubation	NULL
of	NULL
the	NULL
leukemic	NULL
cells	NULL
with	NULL
combinations	NULL
between	NULL
the	NULL
retinoid	NULL
and	NULL
the	NULL
two	NULL
other	NULL
cyto-differentiating	NULL
agents	NULL
leads	NULL
to	NULL
a	NULL
dramatic	NULL
induction	NULL
of	NULL
the	NULL
enzyme	NULL
.	NULL
'	NULL

''	NULL
**	NULL
'	NULL
In	NULL
an	NULL
attempt	NULL
to	NULL
define	NULL
whether	NULL
stimulation	NULL
of	NULL
specific	NULL
RAR	NULL
isoforms	NULL
results	NULL
in	NULL
granulocytic	NULL
maturation	NULL
of	NULL
APL	NULL
cells	NULL
,	NULL
we	NULL
evaluated	NULL
the	NULL
effects	NULL
of	NULL
a	NULL
series	NULL
of	NULL
compounds	NULL
with	NULL
different	NULL
specificities	NULL
for	NULL
RARs	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
LAP	NULL
and	NULL
other	NULL
myeloid	NULL
maturation	NULL
markers	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
G-CSF	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
show	NULL
that	NULL
AM580	NULL
,	NULL
a	NULL
retinobenzoic	NULL
derivative	NULL
originally	NULL
developed	NULL
as	NULL
a	NULL
RARa-specific	NULL
agonist	NULL
,	NULL
has	NULL
a	NULL
selective	NULL
cyto-differentiating	NULL
activity	NULL
on	NULL
PML-RAR-containing	NULL
APL	NULL
blasts	NULL
.	NULL

In	NULL
this	NULL
leukemic	NULL
cell	NULL
type	NULL
,	NULL
the	NULL
compound	NULL
is	NULL
much	NULL
more	NULL
potent	NULL
than	NULL
ATRA	NULL
in	NULL
inducing	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

This	NULL
selective	NULL
action	NULL
is	NULL
correlated	NULL
with	NULL
the	NULL
ability	NULL
of	NULL
AMS80	NULL
to	NULL
transactivate	NULL
reti-noic-acid-responsive-element	NULL
(	NULL
RARE	NULL
)	NULL
-containing	NULL
genes	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PML-RAR	NULL
much	NULL
better	NULL
than	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RARa	NULL
.	NULL

Blood	NULL
,	NULL
Vol	NULL
87	NULL
,	NULL
No	NULL
4	NULL
(	NULL
February	NULL
15	NULL
)	NULL
,	NULL
1996	NULL
:	NULL
pp	NULL
1520-1531	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

CYTO-DIFFERENTIATING	NULL
EFFECTS	NULL
OF	NULL
AM580	NULL
ON	NULL
APL	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
conditions	NULL
and	NULL
reagents	NULL
.	NULL

|	NULL
The	NULL
NB4	NULL
APL	NULL
cell	NULL
line	NULL
``	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
of	NULL
Dr	NULL
Michel	NULL
Lanotte	NULL
(	NULL
Unité	NULL
INSERM	NULL
301	NULL
,	NULL
``	NULL
Ge-netique	NULL
cellulaire	NULL
et	NULL
moleculaire	NULL
des	NULL
leucemies	NULL
``	NULL
``	NULL
)	NULL
.	NULL

HL-60	NULL
leukemic	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
ATCC	NULL
;	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
routinely	NULL
seeded	NULL
at	NULL
4	NULL
X	NULL
10°	NULL
mL	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
;	NULL
GIBCO-BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Cultures	NULL
were	NULL
free	NULL
from	NULL
mycoplasma	NULL
as	NULL
assessed	NULL
using	NULL
the	NULL
Hoechst	NULL
33258	NULL
fluorescent	NULL
dye	NULL
system	NULL
(	NULL
Farbwerke	NULL
Hoechst	NULL
AG	NULL
,	NULL
Frankfurt	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

ATRA	NULL
and	NULL
8-bromo-cAMP	NULL
(	NULL
8-Br-cAMP	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
(	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

The	NULL
compounds	NULL
4-	NULL
(	NULL
5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphtamido	NULL
)	NULL
benzoic	NULL
acid	NULL
(	NULL
AMS80	NULL
)	NULL
and	NULL
4-	NULL
(	NULL
5,6,7.8-tetrahydro-5,5,8,8-tetra-methyl-2-anthracenyl	NULL
)	NULL
benzoic	NULL
acid	NULL
(	NULL
CD367	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
CIRD-Galderma	NULL
(	NULL
Valbonne	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Ethyl	NULL
p-	NULL
[	NULL
(	NULL
E	NULL
)	NULL
-2-	NULL
(	NULL
5,6,7,8-tet-rahydro-5,5,8,8-tetramethy1-2-naphtyl	NULL
)	NULL
-1-p	NULL
-	NULL
ropenyl	NULL
]	NULL
-benzoic	NULL
-	NULL
acid	NULL
(	NULL
TTNPB	NULL
)	NULL
and	NULL
9-cis	NULL
RA	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
Hoffmann-LaRoche	NULL
(	NULL
Nutley	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Stock	NULL
solutions	NULL
of	NULL
the	NULL
various	NULL
retinoids	NULL
(	NULL
10~	NULL
mol/L	NULL
)	NULL
were	NULL
prepared	NULL
in	NULL
dimethylsulfoxide	NULL
under	NULL
dimmed	NULL
light	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
and	NULL
protected	NULL
from	NULL
light	NULL
until	NULL
use	NULL
.	NULL

Recombinant	NULL
human	NULL
G-CSF	NULL
(	NULL
specific	NULL
activity	NULL
,	NULL
10°	NULL
U/mg	NULL
protein	NULL
)	NULL
was	NULL
from	NULL
Amgen	NULL
Inc	NULL
(	NULL
Thousand	NULL
Oaks	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Preparation	NULL
of	NULL
freshly	NULL
isolated	NULL
APL	NULL
and	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
(	NULL
CML	NULL
)	NULL
cells	NULL
.	NULL

-	NULL
Peripheral	NULL
blood	NULL
leukocytes	NULL
from	NULL
5	NULL
CML	NULL
patients	NULL
during	NULL
the	NULL
stable	NULL
phase	NULL
of	NULL
the	NULL
disease	NULL
were	NULL
purified	NULL
to	NULL
90	NULL
%	NULL
homogeneity	NULL
from	NULL
buffy	NULL
coats	NULL
by	NULL
Ficoll-Hypaque	NULL
gradient	NULL
centrifugation	NULL
and	NULL
sedimentation	NULL
on	NULL
dextran	NULL
,	NULL
as	NULL
described	NULL
elsewhere	NULL
.	NULL
``	NULL

''	NULL
Almost	NULL
pure	NULL
preparations	NULL
of	NULL
APL	NULL
cells	NULL
were	NULL
obtained	NULL
by	NULL
dextran	NULL
sedimentation	NULL
of	NULL
bone	NULL
marrow	NULL
aspirates	NULL
from	NULL
4	NULL
patients	NULL
with	NULL
a	NULL
classical	NULL
form	NULL
of	NULL
APL	NULL
(	NULL
M3	NULL
according	NULL
to	NULL
the	NULL
FAB	NULL
classification	NULL
)	NULL
presenting	NULL
the	NULL
typical	NULL
t	NULL
(	NULL
15-17	NULL
)	NULL
chromosomal	NULL
translocation	NULL
.	NULL

These	NULL
cell	NULL
preparations	NULL
consisted	NULL
of	NULL
more	NULL
than	NULL
90	NULL
%	NULL
APL	NULL
blasts	NULL
as	NULL
assessed	NULL
by	NULL
morphol-ogy	NULL
.	NULL

Leukemic	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
cultured	NULL
in	NULL
this	NULL
medium	NULL
in	NULL
the	NULL
various	NULL
experimental	NULL
conditions	NULL
described	NULL
in	NULL
the	NULL
report	NULL
.	NULL

Analysis	NULL
of	NULL
cell	NULL
surface	NULL
markers	NULL
.	NULL

-	NULL
NB4	NULL
,	NULL
HL-60	NULL
,	NULL
or	NULL
APL	NULL
cells	NULL
were	NULL
seeded	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
4	NULL
x	NULL
10°/mL	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
incubated	NULL
for	NULL
4	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
medium	NULL
alone	NULL
or	NULL
medium	NULL
containing	NULL
retinoids	NULL
and/or	NULL
G-CSF	NULL
.	NULL

The	NULL
number	NULL
of	NULL
CD11b*	NULL
and	NULL
CD33*	NULL
cells	NULL
and	NULL
the	NULL
mean	NULL
associated	NULL
fluorescence	NULL
were	NULL
quantitated	NULL
using	NULL
a	NULL
FACScan	NULL
analyzer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Determination	NULL
of	NULL
surface	NULL
markers	NULL
was	NULL
performed	NULL
by	NULL
a	NULL
direct	NULL
immunofluorescence	NULL
assay	NULL
using	NULL
the	NULL
following	NULL
fluorescence	NULL
conjugated	NULL
monoclonal	NULL
antibodies	NULL
purchased	NULL
from	NULL
Becton	NULL
Dickinson	NULL
:	NULL
phycoerythrin	NULL
(	NULL
PE	NULL
)	NULL
-conjugated	NULL
Leu15	NULL
(	NULL
IgG2a	NULL
;	NULL
anti-CD11b	NULL
)	NULL
and	NULL
Leu	NULL
M9	NULL
(	NULL
IgG1	NULL
;	NULL
anti-CD33	NULL
)	NULL
.	NULL

Simultest	NULL
Control	NULL
(	NULL
PE	NULL
conjugates	NULL
1gG1	NULL
and	NULL
IgG2a	NULL
;	NULL
Becton	NULL
Dickinson	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

``	NULL
*	NULL
Measurement	NULL
of	NULL
LAP	NULL
activity	NULL
.	NULL

-	NULL
Approximately	NULL
1	NULL
x	NULL
10°	NULL
NB4	NULL
,	NULL
HL-60	NULL
,	NULL
and	NULL
APL	NULL
fresh	NULL
leukemic	NULL
cells	NULL
or	NULL
CML	NULL
neutrophils	NULL
were	NULL
har-vested	NULL
,	NULL
pelletted	NULL
by	NULL
centrifugation	NULL
at	NULL
400g	NULL
for	NULL
10	NULL
minutes	NULL
,	NULL
washed	NULL
once	NULL
with	NULL
0.9	NULL
%	NULL
NaCl	NULL
,	NULL
and	NULL
centrifuged	NULL
again	NULL
.	NULL

The	NULL
washed	NULL
cell	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
homogenization	NULL
buffer	NULL
(	NULL
1	NULL
mmol/L	NULL
MgCl	NULL
,	NULL
,	NULL
1	NULL
mmol/L	NULL
CaC1	NULL
;	NULL
,	NULL
20	NULL
mmol/L	NULL
ZnCl	NULL
;	NULL
,	NULL
0.1	NULL
mol/L	NULL
NaCl	NULL
,	NULL
0.1	NULL
%	NULL
[	NULL
vol/vol	NULL
]	NULL
Triton	NULL
X-100	NULL
,	NULL
50	NULL
mmol/L	NULL
Tris/HCl	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
and	NULL
disrupted	NULL
by	NULL
vigorous	NULL
pipetting	NULL
.	NULL

The	NULL
homogenate	NULL
was	NULL
used	NULL
for	NULL
the	NULL
LAP	NULL
assay	NULL
,	NULL
which	NULL
was	NULL
performed	NULL
with	NULL
p-nitrophenol	NULL
phosphate	NULL
(	NULL
Sigma	NULL
)	NULL
as	NULL
substrate	NULL
according	NULL
to	NULL
the	NULL
instructions	NULL
of	NULL
the	NULL
manufacturer	NULL
.	NULL

LAP	NULL
activity	NULL
was	NULL
normalized	NULL
for	NULL
the	NULL
content	NULL
of	NULL
protein	NULL
in	NULL
the	NULL
sample	NULL
.	NULL

Proteins	NULL
were	NULL
measured	NULL
according	NULL
to	NULL
the	NULL
Bradford	NULL
method	NULL
``	NULL
``	NULL
using	NULL
BSA	NULL
fraction	NULL
V	NULL
(	NULL
Sigma	NULL
)	NULL
as	NULL
a	NULL
standard	NULL
.	NULL

One	NULL
unit	NULL
of	NULL
LAP	NULL
activity	NULL
is	NULL
defined	NULL
as	NULL
the	NULL
amount	NULL
of	NULL
enzyme	NULL
capable	NULL
of	NULL
transforming	NULL
1	NULL
nmol	NULL
of	NULL
substrate	NULL
in	NULL
1	NULL
minute	NULL
at	NULL
25°C	NULL
.	NULL

Enzyme	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
conditions	NULL
of	NULL
linearity	NULL
relative	NULL
to	NULL
the	NULL
substrate	NULL
and	NULL
to	NULL
the	NULL
concentration	NULL
of	NULL
proteins	NULL
.	NULL

1521	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
prepared	NULL
from	NULL
NB4	NULL
,	NULL
HL-60	NULL
,	NULL
and	NULL
freshly	NULL
isolated	NULL
APL	NULL
cells	NULL
according	NULL
to	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
guanidium	NULL
isothiocyanate/CsCl	NULL
method	NULL
and	NULL
used	NULL
for	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL
``	NULL

''	NULL
The	NULL
probes	NULL
used	NULL
for	NULL
Northern	NULL
blot	NULL
analysis	NULL
were	NULL
a	NULL
full-length	NULL
human	NULL
liver/bone/kidney-type	NULL
(	NULL
L/B/K-type	NULL
)	NULL
alkaline	NULL
phosphatase	NULL
cDNA	NULL
(	NULL
ATCC	NULL
)	NULL
,	NULL
``	NULL
the	NULL
cDNA	NULL
coding	NULL
for	NULL
the	NULL
G-CSF	NULL
receptor	NULL
,	NULL
``	NULL
and	NULL
the	NULL
cDNA	NULL
coding	NULL
for	NULL
the	NULL
human	NULL
glucose-6-phosphate	NULL
dehydrogenase	NULL
(	NULL
GGPDH	NULL
)	NULL
.	NULL
``	NULL

The	NULL
various	NULL
probes	NULL
were	NULL
labeled	NULL
to	NULL
a	NULL
specific	NULL
radioactivity	NULL
of	NULL
1	NULL
to	NULL
2	NULL
x	NULL
10°	NULL
cpm/ug	NULL
by	NULL
using	NULL
hexanucleotide	NULL
primers	NULL
and	NULL
[	NULL
°°P	NULL
]	NULL
dCTP	NULL
.	NULL
``	NULL

Transactivation	NULL
experiments	NULL
.	NULL

|	NULL
Simian	NULL
COS-7	NULL
fibroblasts	NULL
were	NULL
obtained	NULL
from	NULL
ATCC	NULL
and	NULL
routinely	NULL
passaged	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
(	NULL
DMEM	NULL
)	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

Transient	NULL
transfection	NULL
experiments	NULL
were	NULL
performed	NULL
according	NULL
to	NULL
a	NULL
standard	NULL
calcium-phosphate	NULL
coprecipitation	NULL
procedure	NULL
``	NULL
using	NULL
the	NULL
following	NULL
plasmids	NULL
:	NULL
pSGS5-RARa®	NULL
(	NULL
from	NULL
Dr	NULL
P.G	NULL
.	NULL

Pelicci	NULL
,	NULL
Perugia	NULL
,	NULL
Italy	NULL
)	NULL
and	NULL
pSGS-PML/	NULL
RARa®	NULL
containing	NULL
the	NULL
human	NULL
RARa	NULL
and	NULL
PML-RAR	NULL
cDNAs	NULL
,	NULL
respectively	NULL
,	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
SV-40	NULL
early	NULL
T-antigen	NULL
promoter	NULL
enhancer	NULL
;	NULL
TRE-TK-CAT	NULL
,	NULL
containing	NULL
the	NULL
chloramphenicol	NULL
acetyl	NULL
transferase	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
a	NULL
palindromic	NULL
synthetic	NULL
RARE	NULL
placed	NULL
in	NULL
front	NULL
of	NULL
the	NULL
viral	NULL
thymidine	NULL
kinase	NULL
gene	NULL
``	NULL
;	NULL
pSVALBK	NULL
(	NULL
de-nominated	NULL
LAP	NULL
CAT	NULL
in	NULL
this	NULL
report	NULL
)	NULL
,	NULL
containing	NULL
approximately	NULL
4.5	NULL
kb	NULL
of	NULL
the	NULL
5	NULL
flanking	NULL
region	NULL
of	NULL
the	NULL
upstream	NULL
exon	NULL
of	NULL
the	NULL
L/BK-type	NULL
alkaline	NULL
phosphatase	NULL
gene	NULL
placed	NULL
in	NULL
front	NULL
of	NULL
the	NULL
CAT	NULL
reporter	NULL
(	NULL
from	NULL
Dr	NULL
T.	NULL
Kadesch	NULL
,	NULL
Philadelphia	NULL
,	NULL
PA	NULL
)	NULL
;	NULL
and	NULL
pnIsLACZ	NULL
containing	NULL
the	NULL
bacterial	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
early	NULL
T-antigen	NULL
of	NULL
the	NULL
SV40	NULL
enhancer-promoter*	NULL
(	NULL
from	NULL
Dr	NULL
A.	NULL
Weisz	NULL
,	NULL
Napoli	NULL
,	NULL
Italy	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
50	NULL
ng	NULL
each	NULL
of	NULL
RARa	NULL
or	NULL
PML-RAR	NULL
and	NULL
RXRa	NULL
were	NULL
cotransfected	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
the	NULL
reporter	NULL
gene	NULL
(	NULL
TRE-TK	NULL
CAT	NULL
or	NULL
LAP	NULL
CAT	NULL
)	NULL
,	NULL
0.5	NULL
ug	NULL
of	NULL
pnlsLACZ	NULL
,	NULL
and	NULL
pBluscript	NULL
to	NULL
10	NULL
pg	NULL
.	NULL

After	NULL
leaving	NULL
the	NULL
DNA	NULL
coprecipitate	NULL
in	NULL
contact	NULL
with	NULL
cells	NULL
for	NULL
16	NULL
hours	NULL
,	NULL
fresh	NULL
medium	NULL
(	NULL
10	NULL
%	NULL
charcoal	NULL
stripped	NULL
fetal	NULL
calf	NULL
serum	NULL
to	NULL
eliminate	NULL
endoge-nous	NULL
retinoids	NULL
)	NULL
alone	NULL
or	NULL
fresh	NULL
medium	NULL
containing	NULL
ATRA	NULL
or	NULL
AM580	NULL
was	NULL
added	NULL
and	NULL
cells	NULL
were	NULL
further	NULL
incubated	NULL
for	NULL
36	NULL
hours	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
treatment	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
processed	NULL
for	NULL
determination	NULL
of	NULL
CAT	NULL
and	NULL
3-galactosidase	NULL
activity	NULL
.	NULL

CAT	NULL
and	NULL
-galactosidase	NULL
activities	NULL
were	NULL
measured	NULL
on	NULL
cell	NULL
extracts	NULL
according	NULL
to	NULL
standard	NULL
proce-dures	NULL
``	NULL
and	NULL
as	NULL
described	NULL
,	NULL
``	NULL
respectively	NULL
.	NULL

The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
relative	NULL
CAT	NULL
activity	NULL
,	NULL
which	NULL
is	NULL
the	NULL
ratio	NULL
of	NULL
CAT	NULL
activity	NULL
produced	NULL
by	NULL
the	NULL
reporter	NULL
in	NULL
cpm	NULL
of	NULL
acetylated	NULL
chloramphenicol	NULL
divided	NULL
by	NULL
the	NULL
B-galactosidase	NULL
activity	NULL
produced	NULL
by	NULL
pnIsLACZ	NULL
expressed	NULL
in	NULL
absorbance	NULL
units	NULL
at	NULL
420	NULL
nm	NULL
.	NULL

Preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
and	NULL
binding	NULL
experiments	NULL
.	NULL

|	NULL
Nuclear	NULL
extracts	NULL
from	NULL
RARa	NULL
,	NULL
PML-RAR	NULL
,	NULL
and	NULL
mock	NULL
transfected	NULL
COS-7	NULL
cells	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
by	NULL
Nervi	NULL
et	NULL
al	NULL
.	NULL
``	NULL

Briefly	NULL
,	NULL
the	NULL
cell	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
5	NULL
mL	NULL
PTG	NULL
(	NULL
5	NULL
mmol/L	NULL
sodium	NULL
phosphate	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
10	NULL
mmol/L	NULL
thioglycerol	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
aprotinin	NULL
[	NULL
0.15	NULL
umol/	NULL
LJ	NULL
,	NULL
leupeptin	NULL
[	NULL
2	NULL
mmol/L	NULL
]	NULL
,	NULL
and	NULL
phenyImethylsulfonylfluoride	NULL
[	NULL
0.1	NULL
mmol/L	NULL
]	NULL
;	NULL
Boheringer	NULL
)	NULL
and	NULL
homogenized	NULL
with	NULL
a	NULL
Dounce	NULL
homoge-nizer	NULL
.	NULL

The	NULL
pellet	NULL
,	NULL
containing	NULL
the	NULL
cell	NULL
nuclei	NULL
,	NULL
was	NULL
washed	NULL
twice	NULL
with	NULL
2	NULL
mL	NULL
of	NULL
PTG	NULL
buffer	NULL
.	NULL

The	NULL
nuclear	NULL
pellet	NULL
was	NULL
extracted	NULL
in	NULL
10	NULL
mL	NULL
of	NULL
a	NULL
buffer	NULL
containing	NULL
10	NULL
mmol/L	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
8.5	NULL
,	NULL
2	NULL
mmol/L	NULL
dithiothreitol	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
0.8	NULL
mol/L	NULL
KCI	NULL
,	NULL
and	NULL
the	NULL
same	NULL
protease	NULL
inhibitors	NULL
as	NULL
above	NULL
;	NULL
incubated	NULL
for	NULL
1	NULL
hour	NULL
in	NULL
ice	NULL
;	NULL
and	NULL
then	NULL
centrifuged	NULL
at	NULL
130,000g	NULL
for	NULL
30	NULL
minutes	NULL
.	NULL

The	NULL
resulting	NULL
supernatant	NULL
is	NULL
referred	NULL
to	NULL
as	NULL
the	NULL
nuclear	NULL
extract	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
used	NULL
either	NULL
immediately	NULL
or	NULL
after	NULL
storage	NULL
at	NULL
-80°C	NULL
.	NULL

In	NULL
routine	NULL
binding	NULL
assays	NULL
,	NULL
nuclear	NULL
extracts	NULL
(	NULL
200	NULL
to	NULL
400	NULL
LL	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
1	NULL
nmol/L	NULL
[	NULL
°H	NULL
]	NULL
JCD367	NULL
(	NULL
CIRD-Galderma	NULL
;	NULL
specific	NULL
activity	NULL
,	NULL
52.8	NULL
Ci/mmol	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
varying	NULL
concentrations	NULL
of	NULL
CD367	NULL
,	NULL
AMS580	NULL
,	NULL
or	NULL
ATRA	NULL
as	NULL
cold	NULL
competitors	NULL
.	NULL

The	NULL
preparations	NULL
were	NULL
incubated	NULL
for	NULL
18	NULL
hours	NULL
at	NULL
4°C	NULL
and	NULL
directly	NULL
loaded	NULL
on	NULL
a	NULL
Superose	NULL
6HR	NULL
10/30	NULL
(	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
.	NULL

Chromatography	NULL
was	NULL
performed	NULL
in	NULL
isocratic	NULL
conditions	NULL
using	NULL
PTG	NULL
buffer	NULL
containing	NULL
0.4	NULL
mol/L	NULL
KCI	NULL
at	NULL
room	NULL
temperature	NULL
at	NULL
a	NULL
flow	NULL
rate	NULL
of	NULL
0.4	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1522	NULL
ATRA	NULL
9-CISRA	NULL
AMS8O	NULL
0	NULL
GIANNI	NULL
ET	NULL
AL	NULL
TTNPB	NULL
o	NULL
We	NULL
``	NULL
iii	NULL
?	NULL

QED/	NULL
{	NULL
EDAOH\	NULL
o	NULL
cb2oi9e	NULL
_	NULL
,	NULL
,	NULL
cose	NULL
?	NULL

-	NULL
,	NULL
,	NULL
mL/min	NULL
.	NULL

Fractions	NULL
(	NULL
0.4	NULL
mL	NULL
each	NULL
)	NULL
were	NULL
collected	NULL
and	NULL
the	NULL
radioactivity	NULL
in	NULL
each	NULL
fraction	NULL
was	NULL
determined	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
5	NULL
mL	NULL
Filtercount	NULL
(	NULL
Packard	NULL
,	NULL
Meriden	NULL
,	NULL
CT	NULL
)	NULL
.	NULL

Although	NULL
most	NULL
of	NULL
the	NULL
saturation	NULL
or	NULL
competition	NULL
binding	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
this	NULL
methodology	NULL
,	NULL
we	NULL
also	NULL
performed	NULL
experiments	NULL
with	NULL
a	NULL
faster	NULL
technique	NULL
that	NULL
gives	NULL
similar	NULL
results	NULL
and	NULL
allows	NULL
the	NULL
simultaneous	NULL
handling	NULL
of	NULL
a	NULL
large	NULL
number	NULL
of	NULL
samples	NULL
.	NULL
``	NULL

Briefly	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
loaded	NULL
over	NULL
PD10	NULL
desalting	NULL
columns	NULL
(	NULL
Pharmacia	NULL
)	NULL
previously	NULL
washed	NULL
consecutively	NULL
with	NULL
15	NULL
mL	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
10	NULL
mL	NULL
PTG	NULL
buffer	NULL
containing	NULL
0.4	NULL
mol/L	NULL
KCI	NULL
and	NULL
eluted	NULL
with	NULL
the	NULL
same	NULL
buffer	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
first	NULL
2	NULL
mL	NULL
.	NULL

of	NULL
the	NULL
eluted	NULL
buffer	NULL
were	NULL
discarded	NULL
,	NULL
and	NULL
the	NULL
following	NULL
2.5	NULL
mL	NULL
was	NULL
collected	NULL
and	NULL
the	NULL
radioactivity	NULL
measured	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
as	NULL
above	NULL
.	NULL

Linear	NULL
least	NULL
square	NULL
analysis	NULL
of	NULL
the	NULL
scatchard	NULL
plot	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
aid	NULL
of	NULL
the	NULL
computer	NULL
program	NULL
BDATA-EMF	NULL
(	NULL
Vanderbilt	NULL
Medical	NULL
Center	NULL
,	NULL
Nashville	NULL
,	NULL
TN	NULL
)	NULL
.	NULL
``	NULL

The	NULL
retinoid	NULL
concentrations	NULL
that	NULL
inhibit	NULL
50	NULL
%	NULL
of	NULL
the	NULL
total	NULL
specific	NULL
CD367	NULL
binding	NULL
were	NULL
calculated	NULL
using	NULL
the	NULL
nonlinear	NULL
least	NULL
squares	NULL
regression	NULL
analysis	NULL
program	NULL
ALLFIT	NULL
(	NULL
Vanderbilt	NULL
Medical	NULL
Center	NULL
)	NULL
.	NULL
``	NULL

Determination	NULL
of	NULL
intracellular	NULL
levels	NULL
of	NULL
AM3580	NULL
and	NULL
ATRA	NULL
in	NULL
NB4	NULL
and	NULL
HL-60	NULL
cells	NULL
.	NULL

ATRA	NULL
and	NULL
AMS80	NULL
were	NULL
extracted	NULL
from	NULL
NB4	NULL
and	NULL
HL-60	NULL
cells	NULL
with	NULL
acetonitrile	NULL
,	NULL
after	NULL
adding	NULL
the	NULL
internal	NULL
standard	NULL
and	NULL
quantified	NULL
by	NULL
high-performance	NULL
liquid	NULL
chromatography	NULL
with	NULL
UV	NULL
detection	NULL
as	NULL
described	NULL
.	NULL
``	NULL

Drug-free	NULL
cells	NULL
and	NULL
cells	NULL
containing	NULL
known	NULL
amounts	NULL
of	NULL
ATRA	NULL
or	NULL
AMS80	NULL
were	NULL
analyzed	NULL
concurrently	NULL
with	NULL
each	NULL
set	NULL
of	NULL
samples	NULL
.	NULL

Standard	NULL
calibration	NULL
curves	NULL
were	NULL
constructed	NULL
by	NULL
linear	NULL
least	NULL
squares	NULL
regression	NULL
analysis	NULL
of	NULL
the	NULL
plot	NULL
of	NULL
the	NULL
peak-height	NULL
ratios	NULL
between	NULL
the	NULL
compounds	NULL
and	NULL
the	NULL
internal	NULL
standard	NULL
versus	NULL
their	NULL
concentrations	NULL
in	NULL
biologic	NULL
samples	NULL
.	NULL

The	NULL
limit	NULL
of	NULL
detec-tion	NULL
,	NULL
precision	NULL
,	NULL
and	NULL
reproducibility	NULL
were	NULL
as	NULL
previously	NULL
described	NULL
for	NULL
plasma	NULL
analysis	NULL
.	NULL
``	NULL

''	NULL
Area	NULL
under	NULL
the	NULL
curve	NULL
(	NULL
AUC	NULL
)	NULL
values	NULL
were	NULL
calculated	NULL
by	NULL
computer-assisted	NULL
integration	NULL
of	NULL
the	NULL
intracellular	NULL
levels	NULL
of	NULL
AMS580	NULL
or	NULL
ATRA	NULL
measured	NULL
at	NULL
various	NULL
time	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
two	NULL
compounds	NULL
to	NULL
the	NULL
culture	NULL
medium	NULL
.	NULL

RESULTS	NULL
Cyto-differentiating	NULL
effects	NULL
of	NULL
AMS580	NULL
,	NULL
ATRA	NULL
,	NULL
and	NULL
other	NULL
retinoids	NULL
in	NULL
NB4	NULL
and	NULL
HL-60	NULL
cells	NULL
.	NULL

We	NULL
determined	NULL
the	NULL
effects	NULL
of	NULL
AMS580	NULL
,	NULL
CD2019	NULL
,	NULL
and	NULL
CD437	NULL
,	NULL
three	NULL
specific	NULL
ligands	NULL
for	NULL
RARa	NULL
,	NULL
RAR/3	NULL
,	NULL
and	NULL
RAR	NULL
y	NULL
,	NULL
``	NULL
respectively	NULL
,	NULL
on	NULL
the	NULL
granulocytic	NULL
maturation	NULL
of	NULL
NB4	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
tested	NULL
CD367	NULL
``	NULL
and	NULL
TTNPB	NULL
,	NULL
*	NULL
two	NULL
RAR-specific	NULL
ligands	NULL
with	NULL
no	NULL
selectivity	NULL
for	NULL
the	NULL
various	NULL
isoforms	NULL
of	NULL
this	NULL
type	NULL
of	NULL
receptor	NULL
,	NULL
and	NULL
9-cis	NULL
RA	NULL
,	NULL
an	NULL
isomer	NULL
of	NULL
ATRA	NULL
that	NULL
interacts	NULL
with	NULL
both	NULL
RAR	NULL
and	NULL
RXR	NULL
isoforms	NULL
.	NULL
``	NULL

The	NULL
chemical	NULL
structure	NULL
of	NULL
the	NULL
various	NULL
retinoids	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
1	NULL
.	NULL

Granulocytic	NULL
maturation	NULL
of	NULL
NB4	NULL
and	NULL
HL-60	NULL
cells	NULL
was	NULL
initially	NULL
studied	NULL
by	NULL
determining	NULL
the	NULL
levels	NULL
of	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
after	NULL
treatment	NULL
with	NULL
the	NULL
various	NULL
retinoids	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
optimal	NULL
concentrations	NULL
CO437	NULL
on	NULL
on	NULL
(	NULL
‘	NULL
\	NULL
‘	NULL
O	NULL
ok	NULL
26	NULL
0	NULL
Fig	NULL
1	NULL
.	NULL

-	NULL
Chemical	NULL
structure	NULL
of	NULL
ATRA	NULL
and	NULL
the	NULL
other	NULL
retinoids	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

The	NULL
chemical	NULL
structure	NULL
of	NULL
ATRA	NULL
,	NULL
9-cis	NULL
RA	NULL
,	NULL
AM580	NULL
,	NULL
TTNPB	NULL
,	NULL
CD367	NULL
,	NULL
CD2019	NULL
,	NULL
and	NULL
CD437	NULL
is	NULL
indicated	NULL
.	NULL

of	NULL
G-CSF	NULL
.	NULL
``	NULL

In	NULL
our	NULL
experimental	NULL
conditions	NULL
,	NULL
when	NULL
cells	NULL
are	NULL
treated	NULL
with	NULL
retinoids	NULL
alone	NULL
(	NULL
at	NULL
any	NULL
given	NULL
concentration	NULL
)	NULL
or	NULL
G-CSF	NULL
alone	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
,	NULL
no	NULL
increase	NULL
in	NULL
LAP	NULL
expression	NULL
is	NULL
observed	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
2A	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
,	NULL
treatment	NULL
of	NULL
NB4	NULL
cells	NULL
with	NULL
ATRA	NULL
,	NULL
at	NULL
concentrations	NULL
between	NULL
107°	NULL
and	NULL
107°	NULL
mol/L	NULL
,	NULL
leads	NULL
to	NULL
a	NULL
dose-dependent	NULL
and	NULL
robust	NULL
increase	NULL
in	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
.	NULL

Maximal	NULL
induction	NULL
of	NULL
the	NULL
enzyme	NULL
is	NULL
observed	NULL
after	NULL
incubation	NULL
with	NULL
10~	NULL
'	NULL
mol/L	NULL
ATRA	NULL
.	NULL

A	NULL
similar	NULL
dose-response	NULL
curve	NULL
is	NULL
evident	NULL
when	NULL
ATRA	NULL
is	NULL
substituted	NULL
by	NULL
9-cis	NULL
RA	NULL
.	NULL

Interestingly	NULL
,	NULL
TTNPB	NULL
,	NULL
CD367	NULL
,	NULL
and	NULL
AMS8O	NULL
have	NULL
very	NULL
similar	NULL
dose-response	NULL
curves	NULL
and	NULL
cause	NULL
maximal	NULL
induction	NULL
of	NULL
LAP	NULL
at	NULL
concentrations	NULL
that	NULL
are	NULL
two	NULL
logarithms	NULL
lower	NULL
than	NULL
those	NULL
of	NULL
ATRA	NULL
and	NULL
9-cis	NULL
RA	NULL
necessary	NULL
to	NULL
produce	NULL
the	NULL
same	NULL
effect	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
maximal	NULL
level	NULL
of	NULL
induction	NULL
is	NULL
approximately	NULL
threefold	NULL
higher	NULL
after	NULL
exposure	NULL
to	NULL
the	NULL
three	NULL
synthetic	NULL
retinoids	NULL
than	NULL
after	NULL
exposure	NULL
to	NULL
ATRA	NULL
or	NULL
9-cis	NULL
RA	NULL
.	NULL

At	NULL
10~°	NULL
mol/L	NULL
,	NULL
ATRA	NULL
and	NULL
all	NULL
the	NULL
other	NULL
synthetic	NULL
retinoids	NULL
increase	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
submaximally	NULL
,	NULL
which	NULL
is	NULL
the	NULL
consequence	NULL
of	NULL
a	NULL
mild	NULL
cytotoxic	NULL
effect	NULL
.	NULL

The	NULL
compound	NULL
CD2019	NULL
induces	NULL
significant	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
only	NULL
at	NULL
the	NULL
highest	NULL
doses	NULL
tested	NULL
(	NULL
10~°	NULL
and	NULL
10~°	NULL
mol/L	NULL
)	NULL
,	NULL
and	NULL
the	NULL
level	NULL
of	NULL
induction	NULL
is	NULL
several	NULL
fold	NULL
lower	NULL
than	NULL
that	NULL
caused	NULL
by	NULL
ATRA	NULL
or	NULL
9-cis	NULL
RA	NULL
.	NULL

CD437	NULL
is	NULL
totally	NULL
inactive	NULL
in	NULL
this	NULL
assay	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
2B	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
,	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
ATRA	NULL
at	NULL
concentrations	NULL
between	NULL
10~	NULL
``	NULL
and	NULL
10~°	NULL
mol/L	NULL
causes	NULL
an	NULL
almost	NULL
linear	NULL
and	NULL
dose-dependent	NULL
increase	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
LAP	NULL
activity	NULL
.	NULL

However	NULL
,	NULL
at	NULL
optimal	NULL
concentrations	NULL
of	NULL
ATRA	NULL
,	NULL
the	NULL
absolute	NULL
amounts	NULL
of	NULL
LAP	NULL
induced	NULL
in	NULL
HL-60	NULL
are	NULL
threefold	NULL
lower	NULL
than	NULL
those	NULL
observed	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

Up	NULL
to	NULL
107	NULL
``	NULL
mol/L	NULL
,	NULL
a	NULL
similar	NULL
LAP	NULL
induction	NULL
profile	NULL
is	NULL
observed	NULL
when	NULL
HL-60	NULL
cells	NULL
are	NULL
grown	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
and	NULL
9-cis	NULL
RA	NULL
,	NULL
TTNPB	NULL
,	NULL
or	NULL
AMS80	NULL
.	NULL

CD367	NULL
is	NULL
slightly	NULL
more	NULL
effective	NULL
than	NULL
ATRA	NULL
or	NULL
the	NULL
other	NULL
three	NULL
retinoids	NULL
at	NULL
10~	NULL
``	NULL
°	NULL
and	NULL
10~°	NULL
mol/L	NULL
,	NULL
although	NULL
this	NULL
effect	NULL
is	NULL
lost	NULL
at	NULL
higher	NULL
concentrations	NULL
.	NULL

At	NULL
10~°	NULL
mol/L	NULL
,	NULL
ATRA	NULL
is	NULL
more	NULL
active	NULL
than	NULL
all	NULL
the	NULL
other	NULL
retinoids	NULL
and	NULL
this	NULL
higher	NULL
potency	NULL
is	NULL
maintained	NULL
at	NULL
10~°	NULL
mol/L	NULL
,	NULL
although	NULL
,	NULL
at	NULL
this	NULL
concentration	NULL
,	NULL
a	NULL
submaximal	NULL
increase	NULL
in	NULL
LAP	NULL
is	NULL
observed	NULL
.	NULL

Up	NULL
to	NULL
10°	NULL
mol/L	NULL
,	NULL
CD2019	NULL
and	NULL
CD437	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
are	NULL
totally	NULL
inactive	NULL
in	NULL
modulating	NULL
the	NULL
levels	NULL
of	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
data	NULL
indicate	NULL
that	NULL
ATRA	NULL
,	NULL
in	NULL
combination	NULL
with	NULL
G-CSF	NULL
,	NULL
is	NULL
the	NULL
most	NULL
effective	NULL
retinoid	NULL
in	NULL
inducing	NULL
LAP	NULL
in	NULL
HL-60	NULL
.	NULL

In	NULL
further	NULL
experiments	NULL
,	NULL
we	NULL
focused	NULL
our	NULL
attention	NULL
on	NULL
AMS80	NULL
and	NULL
we	NULL
characterized	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
retinoid	NULL
relative	NULL
to	NULL
that	NULL
of	NULL
ATRA	NULL
.	NULL

This	NULL
choice	NULL
was	NULL
suggested	NULL
by	NULL
the	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

CYTO-DIFFERENTIATING	NULL
EFFECTS	NULL
OF	NULL
AM580	NULL
ON	NULL
APL	NULL
®	NULL
€	NULL
®	NULL
3	NULL
40004	NULL
-	NULL
NB4	NULL
a	NULL
.	NULL

&	NULL
E	NULL
3000	NULL
3	NULL
£	NULL
p	NULL
2000	NULL
.	NULL

>	NULL
5	NULL
E	NULL
1000	NULL
o~	NULL
&	NULL
--	NULL
t	NULL
fh	NULL
Lr	NULL
0	NULL
T-	NULL
41	NULL
40	NULL
-9	NULL
080	NULL
9	NULL
6095	NULL
log	NULL
[	NULL
C	NULL
]	NULL
(	NULL
M	NULL
)	NULL
1523	NULL
400	NULL
300	NULL
200	NULL
100	NULL
``	NULL
b	NULL
[	NULL
m	NULL
b	NULL
as	NULL
ro	NULL
s	NULL
c	NULL
log	NULL
[	NULL
C	NULL
]	NULL
(	NULL
M	NULL
)	NULL
Fig	NULL
2	NULL
.	NULL

-	NULL
Induction	NULL
of	NULL
NB4	NULL
and	NULL
HL-60	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
by	NULL
various	NULL
retinoids	NULL
in	NULL
combination	NULL
with	NULL
G-CSF	NULL
.	NULL

NB4	NULL
(	NULL
A	NULL
)	NULL
or	NULL
HL-60	NULL
(	NULL
B	NULL
)	NULL
were	NULL
seeded	NULL
at	NULL
4	NULL
x	NULL
10°	NULL
cells/mL	NULL
and	NULL
treated	NULL
with	NULL
G-CSF	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
or	NULL
with	NULL
G-CSF	NULL
and	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
ATRA	NULL
(	NULL
A	NULL
)	NULL
,	NULL
9-cis	NULL
RA	NULL
(	NULL
M	NULL
)	NULL
,	NULL
CD2019	NULL
(	NULL
A	NULL
)	NULL
,	NULL
TTNPB	NULL
(	NULL
C	NULL
)	NULL
)	NULL
,	NULL
CD367	NULL
(	NULL
O	NULL
)	NULL
,	NULL
CD2019	NULL
(	NULL
¢	NULL
)	NULL
,	NULL
or	NULL
AMS8O	NULL
(	NULL
@	NULL
)	NULL
for	NULL
4	NULL
days	NULL
.	NULL

Cells	NULL
were	NULL
collected	NULL
and	NULL
processed	NULL
for	NULL
the	NULL
determination	NULL
of	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
.	NULL

Treatment	NULL
of	NULL
NB4	NULL
or	NULL
HL-60	NULL
cells	NULL
for	NULL
4	NULL
days	NULL
with	NULL
the	NULL
various	NULL
retinoids	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
G-CSF	NULL
did	NULL
not	NULL
result	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
detectable	NULL
levels	NULL
of	NULL
LAP	NULL
activity	NULL
(	NULL
<	NULL
10	NULL
mU/mg	NULL
protein	NULL
}	NULL
.	NULL

Each	NULL
experimental	NULL
value	NULL
is	NULL
the	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
three	NULL
separate	NULL
cultures	NULL
.	NULL

fact	NULL
that	NULL
CD367	NULL
and	NULL
TTNPB	NULL
are	NULL
very	NULL
strong	NULL
and	NULL
toxic	NULL
retinoids	NULL
in	NULL
vivo	NULL
,	NULL
``	NULL
whereas	NULL
AMS80	NULL
has	NULL
a	NULL
better	NULL
toxicologic	NULL
profile	NULL
(	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

In	NULL
APL	NULL
cells	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
LAP	NULL
is	NULL
induced	NULL
not	NULL
only	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
ATRA	NULL
and	NULL
G-CSF	NULL
but	NULL
also	NULL
by	NULL
the	NULL
combination	NULL
between	NULL
the	NULL
retinoid	NULL
and	NULL
cAMP	NULL
analogs	NULL
.	NULL
``	NULL

Thus	NULL
,	NULL
expression	NULL
of	NULL
LAP	NULL
was	NULL
studied	NULL
in	NULL
NB4	NULL
and	NULL
HL-60	NULL
cells	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
various	NULL
concentrations	NULL
of	NULL
AMS8O0	NULL
or	NULL
ATRA	NULL
and	NULL
an	NULL
optimal	NULL
concentration	NULL
of	NULL
8Br-cAMP	NULL
(	NULL
1	NULL
mmol/L	NULL
)	NULL
.	NULL

In	NULL
these	NULL
experimental	NULL
conditions	NULL
,	NULL
treatment	NULL
of	NULL
NB4	NULL
cells	NULL
with	NULL
AMS580	NULL
results	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
LAP	NULL
at	NULL
concentrations	NULL
100-fold	NULL
lower	NULL
than	NULL
those	NULL
necessary	NULL
to	NULL
obtain	NULL
the	NULL
same	NULL
effect	NULL
with	NULL
ATRA	NULL
.	NULL

In	NULL
HL-60	NULL
cells	NULL
the	NULL
same	NULL
combinations	NULL
are	NULL
ineffective	NULL
``	NULL
(	NULL
data	NULL
not	NULL
reported	NULL
)	NULL
.	NULL

This	NULL
shows	NULL
that	NULL
induction	NULL
of	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
by	NULL
AMS580	NULL
is	NULL
independent	NULL
of	NULL
the	NULL
second	NULL
cyto-differentiating	NULL
stimulus	NULL
used	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
retinoid	NULL
.	NULL

Figure	NULL
3A	NULL
shows	NULL
that	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
(	NULL
10	NULL
ng/	NULL
mL	NULL
)	NULL
,	NULL
induction	NULL
of	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
in	NULL
NB4	NULL
cells	NULL
by	NULL
AMS8O	NULL
and	NULL
ATRA	NULL
is	NULL
the	NULL
result	NULL
of	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
steady-state	NULL
levels	NULL
of	NULL
the	NULL
corresponding	NULL
transcript	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
results	NULL
obtained	NULL
by	NULL
measurement	NULL
of	NULL
LAP	NULL
activity	NULL
,	NULL
AMS8O	NULL
is	NULL
substantially	NULL
more	NULL
active	NULL
than	NULL
ATRA	NULL
in	NULL
causing	NULL
accumulation	NULL
of	NULL
the	NULL
corresponding	NULL
mRNA	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
,	NULL
AMS80	NULL
(	NULL
at	NULL
10~°	NULL
mol/L	NULL
)	NULL
produces	NULL
a	NULL
remarkable	NULL
induction	NULL
in	NULL
LAP	NULL
mRNA	NULL
,	NULL
whereas	NULL
,	NULL
in	NULL
the	NULL
same	NULL
experimental	NULL
conditions	NULL
and	NULL
at	NULL
the	NULL
same	NULL
concentration	NULL
,	NULL
ATRA	NULL
is	NULL
totally	NULL
ineffective	NULL
.	NULL

At	NULL
a	NULL
concentration	NULL
of	NULL
10~	NULL
``	NULL
mol/L	NULL
,	NULL
AMS80	NULL
and	NULL
ATRA	NULL
,	NULL
in	NULL
combination	NULL
with	NULL
G-CSF	NULL
,	NULL
induce	NULL
almost	NULL
the	NULL
same	NULL
level	NULL
of	NULL
LAP	NULL
transcript	NULL
.	NULL

The	NULL
Northern	NULL
blot	NULL
does	NULL
not	NULL
show	NULL
LAP	NULL
mRNA	NULL
upregulation	NULL
on	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
10°	NULL
mol/L	NULL
CD2019	NULL
.	NULL

As	NULL
shown	NULL
by	NULL
Fig	NULL
3B	NULL
,	NULL
in	NULL
HL-60	NULL
cells	NULL
,	NULL
LAP	NULL
mRNA	NULL
accumulation	NULL
is	NULL
more	NULL
dramatic	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ATRA	NULL
+	NULL
G-CSF	NULL
than	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
AMS80	NULL
+	NULL
G-CSF	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
at	NULL
10~°	NULL
mol/L	NULL
and	NULL
10~®	NULL
mol/L	NULL
,	NULL
ATRA	NULL
causes	NULL
a	NULL
10-fold	NULL
and	NULL
threefold	NULL
higher	NULL
upregulation	NULL
of	NULL
LAP	NULL
transcript	NULL
than	NULL
AMS8O0	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
again	NULL
in	NULL
line	NULL
with	NULL
what	NULL
observed	NULL
at	NULL
the	NULL
level	NULL
of	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
effects	NULL
of	NULL
AMS8O0	NULL
and	NULL
ATRA	NULL
on	NULL
other	NULL
granulocytic	NULL
maturation-associated	NULL
markers	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
CD1	NULL
1b	NULL
,	NULL
CD33	NULL
,	NULL
and	NULL
G-CSF	NULL
receptor	NULL
mRNA	NULL
in	NULL
NB4	NULL
and	NULL
HL-60	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
4	NULL
(	NULL
left	NULL
panels	NULL
)	NULL
,	NULL
CD11b	NULL
is	NULL
not	NULL
expressed	NULL
in	NULL
NB4	NULL
in	NULL
basal	NULL
conditions	NULL
,	NULL
whereas	NULL
CD33	NULL
is	NULL
present	NULL
on	NULL
the	NULL
majority	NULL
of	NULL
blasts	NULL
.	NULL

After	NULL
treatment	NULL
with	NULL
ATRA	NULL
for	NULL
4	NULL
days	NULL
,	NULL
the	NULL
number	NULL
of	NULL
NB4	NULL
cells	NULL
expressing	NULL
CD11b	NULL
increases	NULL
,	NULL
starting	NULL
from	NULL
10~	NULL
'	NULL
mol/L	NULL
,	NULL
and	NULL
is	NULL
maximal	NULL
at	NULL
10~°	NULL
mol/L	NULL
.	NULL

Relative	NULL
to	NULL
what	NULL
is	NULL
observed	NULL
with	NULL
ATRA	NULL
,	NULL
the	NULL
dose-response	NULL
curve	NULL
of	NULL
AMS8O0	NULL
for	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
CD1	NULL
1b	NULL
is	NULL
shifted	NULL
towards	NULL
the	NULL
left	NULL
by	NULL
more	NULL
than	NULL
2	NULL
logs	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
number	NULL
of	NULL
CD11b*	NULL
cells	NULL
is	NULL
already	NULL
high	NULL
at	NULL
10~°	NULL
mol/L	NULL
and	NULL
is	NULL
maximal	NULL
at	NULL
10~°	NULL
mol/L	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
ATRA	NULL
and	NULL
AMS580	NULL
,	NULL
G-CSF	NULL
enhances	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
CD1	NULL
1b	NULL
relative	NULL
to	NULL
what	NULL
is	NULL
observed	NULL
with	NULL
the	NULL
retinoids	NULL
alone	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
AMS58O	NULL
,	NULL
this	NULL
effect	NULL
is	NULL
evident	NULL
only	NULL
at	NULL
10~	NULL
``	NULL
mol/L	NULL
,	NULL
whereas	NULL
,	NULL
in	NULL
the	NULL
case	NULL
of	NULL
ATRA	NULL
,	NULL
enhancement	NULL
is	NULL
observed	NULL
at	NULL
levels	NULL
greater	NULL
than	NULL
10~°	NULL
mol/L	NULL
.	NULL

Notice	NULL
that	NULL
,	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
,	NULL
maximal	NULL
upregulation	NULL
of	NULL
CD11b	NULL
by	NULL
ATRA	NULL
is	NULL
lower	NULL
than	NULL
that	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
AMS8O	NULL
alone	NULL
.	NULL

After	NULL
4	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
,	NULL
AMS58O	NULL
is	NULL
more	NULL
potent	NULL
than	NULL
ATRA	NULL
in	NULL
decreasing	NULL
the	NULL
amounts	NULL
of	NULL
CD33	NULL
present	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
NB4	NULL
cells	NULL
,	NULL
although	NULL
the	NULL
difference	NULL
between	NULL
the	NULL
effects	NULL
caused	NULL
by	NULL
the	NULL
two	NULL
retinoids	NULL
is	NULL
less	NULL
remarkable	NULL
than	NULL
that	NULL
observed	NULL
on	NULL
CD11b	NULL
expression	NULL
.	NULL

Data	NULL
on	NULL
CD33	NULL
levels	NULL
after	NULL
treatment	NULL
of	NULL
NB4	NULL
with	NULL
G-CSF	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
,	NULL
ATRA	NULL
(	NULL
10~	NULL
'	NULL
``	NULL
°	NULL
to	NULL
10~°	NULL
mol/L	NULL
)	NULL
,	NULL
or	NULL
AMS580	NULL
(	NULL
10-	NULL
``	NULL
°	NULL
to	NULL
107°	NULL
mol/L	NULL
)	NULL
alone	NULL
are	NULL
not	NULL
documented	NULL
,	NULL
because	NULL
they	NULL
are	NULL
not	NULL
significantly	NULL
different	NULL
from	NULL
what	NULL
is	NULL
observed	NULL
in	NULL
control	NULL
conditions	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
the	NULL
right	NULL
panels	NULL
of	NULL
Fig	NULL
4	NULL
,	NULL
in	NULL
basal	NULL
conditions	NULL
,	NULL
HL-60	NULL
cells	NULL
are	NULL
CD11b~	NULL
and	NULL
CD33*	NULL
.	NULL

ATRA	NULL
causes	NULL
maximal	NULL
induction	NULL
of	NULL
CD11b	NULL
at	NULL
10~	NULL
'	NULL
mol/L	NULL
,	NULL
whereas	NULL
AMS8O	NULL
effectively	NULL
upregulates	NULL
the	NULL
surface	NULL
marker	NULL
only	NULL
at	NULL
10~°	NULL
mol/L	NULL
.	NULL

However	NULL
,	NULL
even	NULL
at	NULL
this	NULL
concentration	NULL
,	NULL
the	NULL
number	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1524	NULL
®	NULL
o	NULL
O	NULL
S	NULL
NB4	NULL
``	NULL
~	NULL
0	NULL
&	NULL
r	NULL
o	NULL
50	NULL
0	NULL
&	NULL
ts	NULL
®	NULL
a_	NULL
0	NULL
[	NULL
3	NULL
]	NULL
LAP	NULL
sll	NULL
=	NULL
wh	NULL
m	NULL
GPD	NULL
WO	NULL
#	NULL
®-	NULL
#	NULL
#	NULL
»	NULL
a	NULL
#	NULL
~	NULL
=	NULL
@	NULL
®	NULL
#	NULL
E	NULL
i	NULL
u	NULL
3	NULL
u.	NULL
w	NULL
3	NULL
u	NULL
2	NULL
i	NULL
985mm	NULL
$	NULL
m§w3wmmmw	NULL
§	NULL
4	NULL
0	NULL
7	NULL
0b	NULL
7	NULL
b	NULL
7°	NULL
a	NULL
9	NULL
a	NULL
9	NULL
6	NULL
9	NULL
g	NULL
C	NULL
°	NULL
ot	NULL
oC	NULL
o	NULL
c	NULL
d	NULL
c	NULL
o	NULL
~	NULL
0	NULL
<	NULL
'	NULL
g¢g+	NULL
<	NULL
+o	NULL
,	NULL
g_y+	NULL
E§£2g252§28§	NULL
{	NULL
$	NULL
=	NULL
on	NULL
<	NULL
®	NULL
3°	NULL
o	NULL
®	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
<	NULL
o	NULL
&	NULL
<	NULL
o	NULL
&	NULL
[	NULL
L	NULL
®	NULL
o	NULL
fas	NULL
8	NULL
5	NULL
5	NULL
§	NULL
§	NULL
<	NULL
5g	NULL
§	NULL
®	NULL
o	NULL
<	NULL
0	NULL
GIANNI	NULL
ET	NULL
AL	NULL
?	NULL

@	NULL
-a	NULL
<	NULL
6	NULL
HL-60	NULL
i	NULL
w	NULL
fol	NULL
&	NULL
R	NULL
o	NULL
50	NULL
®	NULL
&	NULL
ts	NULL
®	NULL
ho	NULL
1—1	NULL
m__	NULL
7	NULL
.	NULL

LAP	NULL
G6PDH	NULL
§b282	NULL
kkk	NULL
3	NULL
:	NULL
©	NULL
9	NULL
%	NULL
0	NULL
4	NULL
o	NULL
%	NULL
9	NULL
2	NULL
0	NULL
80—0—	NULL
(	NULL
9—0—0	NULL
%	NULL
:	NULL
<	NULL
+	NULL
g	NULL
+	NULL
§	NULL
+	NULL
£	NULL
s	NULL
E	NULL
s	NULL
$	NULL
=	NULL
S5	NULL
<	NULL
m	NULL
<	NULL
wm	NULL
Z	NULL
©	NULL
z	NULL
w	NULL
o	NULL
0	NULL
o	NULL
``	NULL
°	NULL
o	NULL
<	NULL
<	NULL
o	NULL
o	NULL
60	NULL
fo	NULL
§	NULL
8	NULL
<	NULL
rs	NULL
bs	NULL
3	NULL
<	NULL
<	NULL
<	NULL
<	NULL
Fig	NULL
3	NULL
.	NULL

Effects	NULL
of	NULL
ATRA	NULL
and	NULL
other	NULL
retinoids	NULL
in	NULL
combination	NULL
with	NULL
G-CSF	NULL
on	NULL
the	NULL
levels	NULL
of	NULL
LAP	NULL
mRNA	NULL
in	NULL
NB4	NULL
and	NULL
HL-60	NULL
cells	NULL
.	NULL

NB4	NULL
(	NULL
A	NULL
)	NULL
or	NULL
HL-60	NULL
(	NULL
B	NULL
)	NULL
cells	NULL
(	NULL
4	NULL
x	NULL
10°/mL	NULL
)	NULL
were	NULL
treated	NULL
for	NULL
4	NULL
days	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
medium	NULL
}	NULL
,	NULL
medium	NULL
containing	NULL
10	NULL
ng/ml	NULL
G-CSF	NULL
,	NULL
and	NULL
medium	NULL
containing	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
ATRA	NULL
,	NULL
CD2019	NULL
,	NULL
or	NULL
AMS80	NULL
,	NULL
each	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
G-CSF	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
extracted	NULL
and	NULL
loaded	NULL
(	NULL
10	NULL
g	NULL
for	NULL
each	NULL
lane	NULL
)	NULL
on	NULL
a	NULL
1	NULL
%	NULL
formaldehyde/agarose	NULL
gel	NULL
.	NULL

RNA	NULL
was	NULL
transferred	NULL
by	NULL
capillarity	NULL
onto	NULL
a	NULL
nylon	NULL
membrane	NULL
that	NULL
was	NULL
subsequently	NULL
processed	NULL
for	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

The	NULL
same	NULL
membrane	NULL
was	NULL
sequentially	NULL
hybridized	NULL
with	NULL
LAP	NULL
and	NULL
GGPDH	NULL
cDNAs	NULL
.	NULL

The	NULL
molecular	NULL
weight	NULL
of	NULL
LAP	NULL
mRNA	NULL
is	NULL
approximately	NULL
2.5	NULL
kb	NULL
and	NULL
that	NULL
of	NULL
G6PDH	NULL
is	NULL
approximately	NULL
2.6	NULL
kb	NULL
.	NULL

Autoradiograms	NULL
were	NULL
quantitated	NULL
by	NULL
densitometry	NULL
and	NULL
the	NULL
intensity	NULL
of	NULL
each	NULL
LAP	NULL
mRNA	NULL
signal	NULL
was	NULL
normalized	NULL
for	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
relative	NULL
GGPDH	NULL
mRNA	NULL
signal	NULL
.	NULL

Results	NULL
are	NULL
indicated	NULL
above	NULL
each	NULL
autoradiogram	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
the	NULL
highest	NULL
value	NULL
(	NULL
AM580	NULL
10°	NULL
mol/L	NULL
+	NULL
G-CSF	NULL
in	NULL
the	NULL
case	NULL
of	NULL
NB4	NULL
and	NULL
ATRA	NULL
10	NULL
°	NULL
mol/	NULL
L	NULL
+	NULL
G-CSF	NULL
in	NULL
the	NULL
case	NULL
of	NULL
HL-60	NULL
cells	NULL
)	NULL
taken	NULL
as	NULL
100.	NULL
of	NULL
CD11b®*	NULL
cells	NULL
is	NULL
significantly	NULL
lower	NULL
than	NULL
that	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ATRA	NULL
.	NULL

In	NULL
this	NULL
cell	NULL
line	NULL
,	NULL
surface	NULL
expression	NULL
of	NULL
CD33	NULL
is	NULL
left	NULL
unaltered	NULL
after	NULL
challenge	NULL
with	NULL
the	NULL
combinations	NULL
of	NULL
G-CSF	NULL
and	NULL
ATRA	NULL
or	NULL
AMS80	NULL
.	NULL

In	NULL
both	NULL
NB4	NULL
and	NULL
HL-60	NULL
cells	NULL
,	NULL
the	NULL
mean	NULL
associated	NULL
fluorescence	NULL
of	NULL
CDI11b*	NULL
and	NULL
CD33	NULL
``	NULL
cells	NULL
is	NULL
very	NULL
similar	NULL
in	NULL
all	NULL
the	NULL
experimental	NULL
conditions	NULL
tested	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
NB4	NULL
cells	NULL
,	NULL
maximal	NULL
expression	NULL
of	NULL
G-CSF	NULL
receptor	NULL
mRNA	NULL
is	NULL
observed	NULL
on	NULL
treatment	NULL
with	NULL
ATRA	NULL
at	NULL
high	NULL
concen-trations	NULL
.	NULL

``	NULL
*	NULL
The	NULL
addition	NULL
of	NULL
G-CSF	NULL
to	NULL
the	NULL
medium	NULL
containing	NULL
ATRA	NULL
does	NULL
not	NULL
further	NULL
enhance	NULL
the	NULL
accumulation	NULL
of	NULL
the	NULL
transcript	NULL
.	NULL
``	NULL

''	NULL
Figure	NULL
5A	NULL
shows	NULL
that	NULL
4	NULL
days	NULL
of	NULL
treatment	NULL
of	NULL
NB4	NULL
cells	NULL
with	NULL
AMS80	NULL
(	NULL
at	NULL
10~®	NULL
mol/L	NULL
)	NULL
leads	NULL
to	NULL
an	NULL
approximately	NULL
sixfold	NULL
increase	NULL
in	NULL
the	NULL
steady-state	NULL
levels	NULL
of	NULL
the	NULL
transcript	NULL
coding	NULL
for	NULL
the	NULL
G-CSF	NULL
receptor	NULL
,	NULL
whereas	NULL
,	NULL
at	NULL
the	NULL
same	NULL
concentration	NULL
,	NULL
ATRA	NULL
does	NULL
not	NULL
significantly	NULL
upregulate	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
this	NULL
mRNA	NULL
.	NULL

At	NULL
10	NULL
~	NULL
mol/L	NULL
,	NULL
ATRA	NULL
and	NULL
AMS80	NULL
are	NULL
both	NULL
effective	NULL
in	NULL
upregulating	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
G-CSF	NULL
receptor	NULL
transcript	NULL
,	NULL
whereas	NULL
G-CSF	NULL
(	NULL
at	NULL
10	NULL
ng/	NULL
mL	NULL
)	NULL
and	NULL
CD2019	NULL
(	NULL
at	NULL
10~®	NULL
and	NULL
10~°	NULL
mol/L	NULL
)	NULL
,	NULL
which	NULL
are	NULL
used	NULL
as	NULL
negative	NULL
controls	NULL
,	NULL
are	NULL
totally	NULL
inactive	NULL
in	NULL
this	NULL
respect	NULL
.	NULL

In	NULL
HL-60	NULL
cells	NULL
(	NULL
Fig	NULL
5B	NULL
)	NULL
,	NULL
only	NULL
ATRA	NULL
at	NULL
10	NULL
~	NULL
``	NULL
mol/L	NULL
is	NULL
capable	NULL
of	NULL
significantly	NULL
augmenting	NULL
(	NULL
approximately	NULL
S5-fold	NULL
)	NULL
the	NULL
relative	NULL
amounts	NULL
of	NULL
the	NULL
cytokine	NULL
receptor	NULL
mRNA	NULL
.	NULL

G-CSF	NULL
(	NULL
at	NULL
10	NULL
ng/	NULL
mL	NULL
)	NULL
and	NULL
AMS80	NULL
(	NULL
at	NULL
10~®	NULL
and	NULL
10~°	NULL
mol/L	NULL
)	NULL
do	NULL
not	NULL
change	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
mRNA	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
data	NULL
so	NULL
far	NULL
presented	NULL
show	NULL
that	NULL
AMS8O0	NULL
is	NULL
a	NULL
more	NULL
powerful	NULL
cyto-differentiating	NULL
agent	NULL
than	NULL
ATRA	NULL
in	NULL
NB4	NULL
,	NULL
whereas	NULL
it	NULL
is	NULL
less	NULL
potent	NULL
than	NULL
the	NULL
natural	NULL
retinoid	NULL
in	NULL
HL-60	NULL
cells	NULL
.	NULL

The	NULL
selective	NULL
cyto-differentiating	NULL
action	NULL
of	NULL
AMS80	NULL
on	NULL
NB4	NULL
is	NULL
not	NULL
accompanied	NULL
by	NULL
a	NULL
similar	NULL
selectivity	NULL
on	NULL
cell	NULL
growth	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
at	NULL
the	NULL
concentrations	NULL
tested	NULL
(	NULL
10~®	NULL
mol/L	NULL
for	NULL
NB4	NULL
and	NULL
10~°	NULL
mol/L	NULL
for	NULL
HL-60	NULL
)	NULL
,	NULL
AMS80	NULL
and	NULL
ATRA	NULL
show	NULL
equivalent	NULL
levels	NULL
of	NULL
growth	NULL
inhibition	NULL
in	NULL
both	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
pharmacodynamic	NULL
effects	NULL
do	NULL
not	NULL
explain	NULL
the	NULL
phenomenon	NULL
,	NULL
because	NULL
the	NULL
peak	NULL
intracellular	NULL
levels	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
rate	NULL
of	NULL
accumulation	NULL
and	NULL
disappearance	NULL
of	NULL
the	NULL
two	NULL
compounds	NULL
,	NULL
are	NULL
similar	NULL
in	NULL
both	NULL
cell	NULL
lines	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
over	NULL
a	NULL
4-day	NULL
period	NULL
,	NULL
the	NULL
calculated	NULL
AUCs	NULL
of	NULL
AMS80	NULL
and	NULL
ATRA	NULL
are	NULL
13.4	NULL
and	NULL
10.5	NULL
ng/10°	NULL
cells	NULL
per	NULL
day	NULL
for	NULL
NB4	NULL
and	NULL
12.4	NULL
and	NULL
6.1	NULL
ng/10°	NULL
cells	NULL
per	NULL
day	NULL
for	NULL
HL-60	NULL
,	NULL
which	NULL
does	NULL
not	NULL
correlate	NULL
with	NULL
the	NULL
relative	NULL
biologic	NULL
activity	NULL
of	NULL
AMS80	NULL
and	NULL
ATRA	NULL
in	NULL
the	NULL
two	NULL
cell	NULL
types	NULL
.	NULL

Cyto-differentiating	NULL
effects	NULL
of	NULL
AM580	NULL
and	NULL
ATRA	NULL
in	NULL
freshly	NULL
isolated	NULL
APL	NULL
and	NULL
CML	NULL
cells	NULL
.	NULL

As	NULL
NB4	NULL
expresses	NULL
PML-RAR	NULL
,	NULL
whereas	NULL
HL-60	NULL
does	NULL
not	NULL
express	NULL
it	NULL
,	NULL
the	NULL
data	NULL
obtained	NULL
in	NULL
the	NULL
two	NULL
APL	NULL
experimental	NULL
models	NULL
suggest	NULL
that	NULL
AMS80	NULL
cyto-differentiating	NULL
activity	NULL
may	NULL
be	NULL
higher	NULL
in	NULL
cells	NULL
containing	NULL
the	NULL
aberrant	NULL
retinoic	NULL
acid	NULL
receptor	NULL
.	NULL

To	NULL
support	NULL
this	NULL
hypothe-sis	NULL
,	NULL
we	NULL
studied	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
in	NULL
freshly	NULL
isolated	NULL
APL	NULL
cells	NULL
and	NULL
CML	NULL
granulocytes	NULL
challenged	NULL
in	NULL
vitro	NULL
with	NULL
AMS80	NULL
and	NULL
ATRA	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
G-CSF	NULL
.	NULL

CML	NULL
granulocytes	NULL
represent	NULL
a	NULL
useful	NULL
source	NULL
of	NULL
myeloid	NULL
cells	NULL
lacking	NULL
PML-RAR	NULL
,	NULL
because	NULL
they	NULL
express	NULL
RARa	NULL
(	NULL
unpub-	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

CYTO-DIFFERENTIATING	NULL
EFFECTS	NULL
OF	NULL
AM580	NULL
ON	NULL
APL	NULL
NB4	NULL
100	NULL
EH	NULL
©	NULL
o	NULL
®	NULL
.2	NULL
95	NULL
9	NULL
50	NULL
2	NULL
A	NULL
O	NULL
a	NULL
04	NULL
0	NULL
4100-800	NULL
60004	NULL
a	NULL
19	NULL
8	NULL
.	NULL

:	NULL
%	NULL
fel	NULL
.2	NULL
Ro	NULL
4	NULL
)	NULL
&	NULL
50	NULL
C	NULL
)	NULL
&	NULL
Q	NULL
O	NULL
a	NULL
0	NULL
mA	NULL
--	NULL
-	NULL
--	NULL
-	NULL
--	NULL
A	NULL
0	NULL
10	NULL
-8	NULL
-6	NULL
-4	NULL
log	NULL
[	NULL
C	NULL
]	NULL
(	NULL
M	NULL
)	NULL
1525	NULL
HL6O	NULL
100	NULL
50	NULL
§	NULL
0	NULL
0	NULL
-10	NULL
_	NULL
-8	NULL
-6	NULL
-4	NULL
100	NULL
AW	NULL
0	NULL
0	NULL
400-800	NULL
600044	NULL
log	NULL
[	NULL
C	NULL
]	NULL
(	NULL
M	NULL
)	NULL
Fig	NULL
4	NULL
.	NULL

Effect	NULL
of	NULL
AM580	NULL
,	NULL
ATRA	NULL
,	NULL
and	NULL
the	NULL
combination	NULL
of	NULL
the	NULL
two	NULL
compounds	NULL
with	NULL
G-CSF	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
myeloid	NULL
surface	NULL
markers	NULL
CD11b	NULL
and	NULL
CD33	NULL
.	NULL

NB4	NULL
cells	NULL
(	NULL
left	NULL
panels	NULL
)	NULL
and	NULL
HL6O	NULL
cells	NULL
(	NULL
right	NULL
panels	NULL
)	NULL
were	NULL
seeded	NULL
at	NULL
4	NULL
x	NULL
10°	NULL
cells/mL	NULL
and	NULL
incubated	NULL
for	NULL
4	NULL
days	NULL
in	NULL
medium	NULL
containing	NULL
increasing	NULL
concentrations	NULL
of	NULL
ATRA	NULL
(	NULL
triangles	NULL
)	NULL
or	NULL
AMS8O	NULL
(	NULL
circles	NULL
)	NULL
either	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
open	NULL
symbols	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
ng/	NULL
mL	NULL
G-CSF	NULL
(	NULL
solid	NULL
symbols	NULL
)	NULL
.	NULL

The	NULL
number	NULL
of	NULL
cells	NULL
positive	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
CD11b	NULL
(	NULL
upper	NULL
panels	NULL
}	NULL
and	NULL
CD33	NULL
(	NULL
lower	NULL
panels	NULL
)	NULL
were	NULL
quantitated	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

For	NULL
each	NULL
experimental	NULL
point	NULL
,	NULL
appropriate	NULL
controls	NULL
consisting	NULL
of	NULL
cells	NULL
decorated	NULL
with	NULL
an	NULL
irrelevant	NULL
monoclonal	NULL
antibody	NULL
of	NULL
the	NULL
same	NULL
isotype	NULL
were	NULL
performed	NULL
.	NULL

In	NULL
these	NULL
controls	NULL
,	NULL
less	NULL
than	NULL
2	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
show	NULL
background	NULL
fluorescence	NULL
;	NULL
thus	NULL
the	NULL
results	NULL
are	NULL
not	NULL
presented	NULL
in	NULL
the	NULL
figure	NULL
.	NULL

lished	NULL
results	NULL
)	NULL
and	NULL
respond	NULL
to	NULL
the	NULL
challenge	NULL
with	NULL
combinations	NULL
of	NULL
ATRA	NULL
and	NULL
G-CSF	NULL
with	NULL
an	NULL
induction	NULL
of	NULL
LAP	NULL
.	NULL
``	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
6	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
ng/mL	NULL
G-CSF	NULL
,	NULL
AM580	NULL
maximally	NULL
induces	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
at	NULL
concentrations	NULL
that	NULL
are	NULL
one	NULL
logarithm	NULL
lower	NULL
than	NULL
those	NULL
necessary	NULL
to	NULL
obtain	NULL
the	NULL
same	NULL
effect	NULL
with	NULL
ATRA	NULL
.	NULL

However	NULL
,	NULL
individual	NULL
variability	NULL
in	NULL
the	NULL
shape	NULL
of	NULL
the	NULL
dose-response	NULL
curve	NULL
and	NULL
in	NULL
the	NULL
concentration	NULL
of	NULL
the	NULL
two	NULL
retinoids	NULL
causing	NULL
maximal	NULL
induction	NULL
of	NULL
LAP	NULL
is	NULL
evident	NULL
.	NULL

Indeed	NULL
,	NULL
APL	NULL
cells	NULL
from	NULL
patients	NULL
no	NULL
.	NULL

2	NULL
and	NULL
3	NULL
,	NULL
respectively	NULL
,	NULL
are	NULL
the	NULL
most	NULL
and	NULL
the	NULL
least	NULL
sensitive	NULL
to	NULL
the	NULL
effects	NULL
of	NULL
both	NULL
AMS8O	NULL
and	NULL
ATRA	NULL
.	NULL

After	NULL
treatment	NULL
of	NULL
CML	NULL
granulocytes	NULL
for	NULL
3	NULL
days	NULL
with	NULL
10	NULL
ng/mL	NULL
G-CSF	NULL
and	NULL
increasing	NULL
concentrations	NULL
of	NULL
ATRA	NULL
or	NULL
AMS80	NULL
,	NULL
a	NULL
dose-dependent	NULL
induction	NULL
of	NULL
LAP	NULL
is	NULL
evident	NULL
.	NULL

In	NULL
all	NULL
the	NULL
cases	NULL
ana-lyzed	NULL
,	NULL
ATRA	NULL
is	NULL
equally	NULL
effective	NULL
(	NULL
patients	NULL
no	NULL
.	NULL

1	NULL
and	NULL
4	NULL
)	NULL
or	NULL
more	NULL
potent	NULL
(	NULL
patients	NULL
no	NULL
.	NULL

2	NULL
,	NULL
3	NULL
,	NULL
and	NULL
5	NULL
)	NULL
than	NULL
AMS580	NULL
in	NULL
inducing	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
.	NULL

In	NULL
freshly	NULL
isolated	NULL
APL	NULL
cells	NULL
,	NULL
induction	NULL
of	NULL
LAP	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
G-CSF	NULL
and	NULL
ATRA	NULL
or	NULL
AMS58O0	NULL
is	NULL
the	NULL
consequence	NULL
of	NULL
an	NULL
increased	NULL
accumulation	NULL
of	NULL
the	NULL
corresponding	NULL
transcript	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
Northern	NULL
blot	NULL
experiments	NULL
performed	NULL
on	NULL
RNA	NULL
extracted	NULL
from	NULL
the	NULL
blasts	NULL
of	NULL
APL	NULL
patient	NULL
no	NULL
.	NULL

4	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
7	NULL
,	NULL
AMS80	NULL
is	NULL
more	NULL
effective	NULL
than	NULL
ATRA	NULL
in	NULL
inducing	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
CD11b	NULL
in	NULL
APL	NULL
cells	NULL
derived	NULL
from	NULL
patient	NULL
no	NULL
.	NULL

1	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
AMS80	NULL
at	NULL
10~°	NULL
mol/L	NULL
is	NULL
sufficient	NULL
to	NULL
cause	NULL
the	NULL
appearance	NULL
of	NULL
CD11b	NULL
on	NULL
the	NULL
majority	NULL
of	NULL
APL	NULL
cells	NULL
and	NULL
higher	NULL
concentrations	NULL
of	NULL
the	NULL
retinoid	NULL
do	NULL
not	NULL
give	NULL
rise	NULL
to	NULL
a	NULL
further	NULL
recruitment	NULL
of	NULL
positive	NULL
cells	NULL
or	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
mean	NULL
associated	NULL
fluorescence	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
for	NULL
ATRA	NULL
,	NULL
a	NULL
concentration	NULL
of	NULL
10~°	NULL
mol/L	NULL
is	NULL
necessary	NULL
to	NULL
induce	NULL
maximal	NULL
expression	NULL
of	NULL
CD11b	NULL
on	NULL
the	NULL
majority	NULL
of	NULL
APL	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
particular	NULL
APL	NULL
case	NULL
,	NULL
CD33	NULL
is	NULL
not	NULL
modulated	NULL
by	NULL
either	NULL
AMS8O	NULL
or	NULL
ATRA	NULL
,	NULL
and	NULL
CD11b	NULL
is	NULL
a	NULL
more	NULL
sensitive	NULL
differentiation	NULL
marker	NULL
than	NULL
LAP	NULL
.	NULL

With	NULL
respect	NULL
to	NULL
the	NULL
last	NULL
point	NULL
,	NULL
CD1ib	NULL
is	NULL
upregulated	NULL
at	NULL
concentrations	NULL
of	NULL
both	NULL
AMS80	NULL
and	NULL
ATRA	NULL
that	NULL
are	NULL
lower	NULL
than	NULL
the	NULL
respective	NULL
concentrations	NULL
of	NULL
the	NULL
two	NULL
retinoids	NULL
necessary	NULL
to	NULL
induce	NULL
LAP	NULL
in	NULL
combination	NULL
with	NULL
G-CSF	NULL
(	NULL
compare	NULL
Fig	NULL
7	NULL
with	NULL
Fig	NULL
6	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
analysis	NULL
was	NULL
conducted	NULL
on	NULL
a	NULL
second	NULL
APL	NULL
case	NULL
(	NULL
patient	NULL
no	NULL
.	NULL

4	NULL
)	NULL
,	NULL
where	NULL
maximal	NULL
induction	NULL
of	NULL
CD11lb	NULL
was	NULL
observed	NULL
at	NULL
10~°	NULL
mol/L	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
AMS580	NULL
,	NULL
and	NULL
at	NULL
10~®	NULL
mol/L	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ATRA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
AM5380	NULL
and	NULL
ATRA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RARa	NULL
and	NULL
PML-RAR	NULL
.	NULL

-	NULL
The	NULL
selective	NULL
cyto-differentiating	NULL
action	NULL
of	NULL
AMS8O	NULL
on	NULL
APL	NULL
cells	NULL
may	NULL
be	NULL
related	NULL
to	NULL
a	NULL
peculiar	NULL
capacity	NULL
of	NULL
the	NULL
retinoid	NULL
to	NULL
interact	NULL
with	NULL
PML-RAR	NULL
.	NULL

To	NULL
test	NULL
this	NULL
hy-pothesis	NULL
,	NULL
we	NULL
evaluated	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
retinobenzoic	NULL
compound	NULL
to	NULL
displace	NULL
the	NULL
binding	NULL
of	NULL
CD367	NULL
on	NULL
PML-RAR	NULL
and	NULL
RARa	NULL
,	NULL
because	NULL
direct	NULL
binding	NULL
experiments	NULL
are	NULL
prevented	NULL
by	NULL
the	NULL
lack	NULL
of	NULL
availability	NULL
of	NULL
radiolabeled	NULL
AMS8O0	NULL
.	NULL

CD367	NULL
was	NULL
selected	NULL
as	NULL
the	NULL
ligand	NULL
,	NULL
because	NULL
it	NULL
binds	NULL
to	NULL
the	NULL
various	NULL
forms	NULL
of	NULL
RAR	NULL
with	NULL
the	NULL
same	NULL
affinity	NULL
as	NULL
ATRA	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
this	NULL
synthetic	NULL
compound	NULL
is	NULL
more	NULL
stable	NULL
and	NULL
gives	NULL
lower	NULL
nonspe-cific	NULL
binding	NULL
than	NULL
the	NULL
natural	NULL
retinoid	NULL
.	NULL
``	NULL

Binding	NULL
experiments	NULL
were	NULL
performed	NULL
on	NULL
nuclear	NULL
extracts	NULL
of	NULL
COS-7	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
cDNA	NULL
encoding	NULL
PML-RAR	NULL
or	NULL
RARa	NULL
.	NULL

The	NULL
free	NULL
form	NULL
of	NULL
radiolabeled	NULL
CD367	NULL
was	NULL
separated	NULL
from	NULL
that	NULL
bound	NULL
to	NULL
PML-RAR	NULL
or	NULL
RARa	NULL
on	NULL
size	NULL
exclusion	NULL
chroma-	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1526	NULL
®	NULL
e	NULL
100	NULL
,	NULL
NB4	NULL
C	NULL
&	NULL
©	NULL
C	NULL
&	NULL
-	NULL
50	NULL
B	NULL
€	NULL
°	NULL
ol	NULL
|	NULL
tg	NULL
c-csrn	NULL
WWP	NULL
Q	NULL
o	NULL
~U	NULL
O	NULL
hu	NULL
m	NULL
gou	NULL
E	NULL
5	NULL
&	NULL
&	NULL
s	NULL
z	NULL
a	NULL
Bou	NULL
r	NULL
1	NULL
4	NULL
o	NULL
a	NULL
gdoooooo	NULL
3	NULL
<	NULL
Oo	NULL
O	NULL
<	NULL
O	NULL
o	NULL
mwv—	NULL
C	NULL
~-Fngmg	NULL
<	NULL
3	NULL
A	NULL
<	NULL
3	NULL
8A	NULL
0	NULL
0	NULL
GIANNI	NULL
ET	NULL
AL	NULL
c	NULL
1004	NULL
HL-60	NULL
.6	NULL
A	NULL
CC	NULL
on	NULL
®	NULL
-	NULL
50	NULL
@	NULL
.2	NULL
t	NULL
@	NULL
0	NULL
G-CSF-R	NULL
#	NULL
»	NULL
wis	NULL
on	NULL
,	NULL
e	NULL
cero	NULL
:	NULL
a	NULL
»	NULL
@	NULL
gp	NULL
@	NULL
iige	NULL
CPCB	NULL
go	NULL
u	NULL
2	NULL
3	NULL
3s	NULL
=	NULL
3	NULL
8	NULL
®	NULL
»	NULL
o	NULL
»	NULL
§	NULL
I1	NULL
o	NULL
o	NULL
o	NULL
o	NULL
EOv—Fg—	NULL
[	NULL
«	NULL
]	NULL
éécooo	NULL
&	NULL
g	NULL
§	NULL
§	NULL
\	NULL
<	NULL
%	NULL
%	NULL
Fig	NULL
5	NULL
.	NULL

Effects	NULL
of	NULL
AM580	NULL
,	NULL
ATRA	NULL
,	NULL
CD2019	NULL
,	NULL
and	NULL
G-CSF	NULL
on	NULL
the	NULL
levels	NULL
of	NULL
G-CSF	NULL
receptor	NULL
mRNA	NULL
in	NULL
NB4	NULL
and	NULL
HL-60	NULL
cells	NULL
.	NULL

NB4	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
or	NULL
HL-60	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
cells	NULL
(	NULL
4	NULL
x	NULL
10°/mL	NULL
)	NULL
were	NULL
treated	NULL
for	NULL
4	NULL
days	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
medium	NULL
)	NULL
,	NULL
medium	NULL
containing	NULL
10	NULL
ng/mL	NULL
G-CSF	NULL
,	NULL
and	NULL
medium	NULL
containing	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
AM580	NULL
,	NULL
ATRA	NULL
,	NULL
or	NULL
CD2019	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
extracted	NULL
and	NULL
loaded	NULL
(	NULL
10	NULL
mg	NULL
for	NULL
each	NULL
lane	NULL
)	NULL
on	NULL
a	NULL
1	NULL
%	NULL
formaldehyde/agarose	NULL
gel	NULL
.	NULL

RNA	NULL
was	NULL
transferred	NULL
by	NULL
capillarity	NULL
onto	NULL
a	NULL
nylon	NULL
membrane	NULL
that	NULL
was	NULL
subsequently	NULL
processed	NULL
for	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

The	NULL
same	NULL
membrane	NULL
was	NULL
sequentially	NULL
hybridized	NULL
with	NULL
the	NULL
G-CSF	NULL
receptor	NULL
(	NULL
G-CSF-R	NULL
)	NULL
and	NULL
G6PDH	NULL
cDNAs	NULL
.	NULL

The	NULL
molecular	NULL
weight	NULL
of	NULL
the	NULL
G-CSF	NULL
receptor	NULL
mRNA	NULL
is	NULL
approximately	NULL
3.0	NULL
kb	NULL
and	NULL
that	NULL
of	NULL
GGPDH	NULL
is	NULL
approximately	NULL
2.6	NULL
kb	NULL
.	NULL

Autoradiograms	NULL
were	NULL
quantitated	NULL
by	NULL
densitometry	NULL
and	NULL
the	NULL
intensity	NULL
of	NULL
each	NULL
G-CSF	NULL
receptor	NULL
mRNA	NULL
signal	NULL
was	NULL
normalized	NULL
for	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
relative	NULL
G6PDH	NULL
mRNA	NULL
signal	NULL
.	NULL

Results	NULL
are	NULL
indicated	NULL
above	NULL
each	NULL
autoradiogram	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
the	NULL
highest	NULL
value	NULL
(	NULL
AM5S80	NULL
10~°	NULL
mol/L	NULL
in	NULL
the	NULL
case	NULL
of	NULL
NB4	NULL
and	NULL
ATRA	NULL
10~°	NULL
mol/L	NULL
in	NULL
the	NULL
case	NULL
of	NULL
HL-60	NULL
cells	NULL
)	NULL
taken	NULL
as	NULL
100.	NULL
tography	NULL
.	NULL

Typical	NULL
chromatograms	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
8A	NULL
.	NULL

RARa-bound	NULL
CD367	NULL
elutes	NULL
in	NULL
a	NULL
discrete	NULL
peak	NULL
at	NULL
an	NULL
apparent	NULL
molecular	NULL
mass	NULL
of	NULL
around	NULL
50	NULL
to	NULL
60	NULL
kD	NULL
(	NULL
fractions	NULL
No	NULL
.	NULL

31-36	NULL
)	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
calibration	NULL
of	NULL
the	NULL
column	NULL
with	NULL
appropriate	NULL
proteins	NULL
of	NULL
known	NULL
molecular	NULL
weight	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
is	NULL
the	NULL
expected	NULL
molecular	NULL
weight	NULL
of	NULL
RARa	NULL
.	NULL

``	NULL
``	NULL
*	NULL
``	NULL
The	NULL
elution	NULL
profile	NULL
of	NULL
PML-RAR-bound	NULL
CD367	NULL
is	NULL
more	NULL
complex	NULL
and	NULL
consists	NULL
of	NULL
two	NULL
peaks	NULL
.	NULL

A	NULL
major	NULL
peak	NULL
,	NULL
representing	NULL
approximately	NULL
80	NULL
%	NULL
of	NULL
the	NULL
bound	NULL
radiactivity	NULL
,	NULL
which	NULL
elutes	NULL
with	NULL
the	NULL
void	NULL
volume	NULL
of	NULL
the	NULL
column	NULL
(	NULL
fractions	NULL
no	NULL
.	NULL

21	NULL
through	NULL
27	NULL
)	NULL
,	NULL
and	NULL
a	NULL
minor	NULL
one	NULL
that	NULL
elutes	NULL
at	NULL
a	NULL
molecular	NULL
mass	NULL
of	NULL
approximately	NULL
100	NULL
kD	NULL
(	NULL
fractions	NULL
no	NULL
.	NULL

30	NULL
through	NULL
34	NULL
)	NULL
.	NULL

The	NULL
first	NULL
PML-RAR	NULL
peak	NULL
represents	NULL
aggregates	NULL
of	NULL
the	NULL
recep-	NULL
tor	NULL
,	NULL
``	NULL
``	NULL
***	NULL
``	NULL
and	NULL
the	NULL
second	NULL
one	NULL
is	NULL
probably	NULL
the	NULL
monomeric	NULL
form	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

``	NULL
``	NULL
**	NULL
We	NULL
observed	NULL
that	NULL
the	NULL
proportion	NULL
of	NULL
the	NULL
two	NULL
PML-RAR	NULL
species	NULL
is	NULL
always	NULL
the	NULL
same	NULL
,	NULL
as	NULL
determined	NULL
in	NULL
a	NULL
large	NULL
series	NULL
of	NULL
independent	NULL
experiments	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
saturation	NULL
curve	NULL
of	NULL
radiolabeled	NULL
CD367	NULL
is	NULL
the	NULL
same	NULL
for	NULL
the	NULL
two	NULL
peaks	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
CD367-associated	NULL
radioactivity	NULL
is	NULL
displaced	NULL
from	NULL
the	NULL
two	NULL
peaks	NULL
of	NULL
protein	NULL
by	NULL
cold	NULL
C€D367	NULL
,	NULL
ATRA	NULL
,	NULL
and	NULL
AMS580	NULL
with	NULL
a	NULL
similar	NULL
Ki	NULL
.	NULL

Thus	NULL
,	NULL
determination	NULL
of	NULL
PML-RAR	NULL
binding	NULL
constants	NULL
of	NULL
the	NULL
various	NULL
retinoids	NULL
is	NULL
the	NULL
same	NULL
,	NULL
regardless	NULL
of	NULL
the	NULL
fact	NULL
that	NULL
analysis	NULL
is	NULL
conducted	NULL
on	NULL
peak	NULL
I	NULL
,	NULL
peak	NULL
II	NULL
,	NULL
or	NULL
the	NULL
combinations	NULL
of	NULL
the	NULL
two	NULL
peaks	NULL
.	NULL

The	NULL
nuclear	NULL
extract	NULL
obtained	NULL
from	NULL
untransfected	NULL
COS-7	NULL
cells	NULL
bind	NULL
less	NULL
than	NULL
1	NULL
%	NULL
of	NULL
the	NULL
CD367	NULL
bound	NULL
to	NULL
that	NULL
derived	NULL
from	NULL
cells	NULL
transfected	NULL
with	NULL
PML-RAR	NULL
or	NULL
RARa	NULL
.	NULL

Radiolabeled	NULL
CD367	NULL
is	NULL
completely	NULL
displaced	NULL
from	NULL
both	NULL
retinoid	NULL
receptors	NULL
by	NULL
a	NULL
200-fold	NULL
excess	NULL
of	NULL
the	NULL
cold	NULL
ligand	NULL
.	NULL

With	NULL
the	NULL
use	NULL
of	NULL
this	NULL
binding	NULL
assay	NULL
,	NULL
we	NULL
generated	NULL
saturation	NULL
curves	NULL
that	NULL
showed	NULL
that	NULL
the	NULL
Kd	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
tritiated	NULL
CD367	NULL
to	NULL
both	NULL
PML-RAR	NULL
and	NULL
RARa	NULL
is	NULL
the	NULL
same	NULL
and	NULL
is	NULL
approximately	NULL
1	NULL
nmol/L	NULL
.	NULL

Using	NULL
this	NULL
concentration	NULL
of	NULL
radiolabeled	NULL
CD367	NULL
,	NULL
the	NULL
binding	NULL
of	NULL
this	NULL
retinoid	NULL
to	NULL
PML-RAR	NULL
and	NULL
RARa	NULL
was	NULL
displaced	NULL
by	NULL
increasing	NULL
concentrations	NULL
of	NULL
ATRA	NULL
or	NULL
AMS80	NULL
.	NULL

Typical	NULL
Hill	NULL
's	NULL
plots	NULL
for	NULL
ATRA	NULL
and	NULL
AMS8O	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
8B	NULL
.	NULL

The	NULL
Ki	NULL
(	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
3	NULL
independent	NULL
experiments	NULL
)	NULL
of	NULL
AMS80	NULL
and	NULL
ATRA	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
CD367	NULL
binding	NULL
to	NULL
PML-RAR	NULL
and	NULL
RARa	NULL
,	NULL
respectively	NULL
,	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

ATRA	NULL
has	NULL
an	NULL
affinity	NULL
for	NULL
PML-RAR	NULL
that	NULL
is	NULL
almost	NULL
fourfold	NULL
lower	NULL
than	NULL
that	NULL
for	NULL
RARa	NULL
,	NULL
whereas	NULL
no	NULL
statistically	NULL
significant	NULL
difference	NULL
between	NULL
the	NULL
binding	NULL
of	NULL
AMS80	NULL
to	NULL
the	NULL
two	NULL
receptors	NULL
is	NULL
observed	NULL
.	NULL

In	NULL
both	NULL
the	NULL
cases	NULL
of	NULL
PML-RAR	NULL
and	NULL
RARa	NULL
,	NULL
the	NULL
Ki	NULL
of	NULL
AMS80	NULL
is	NULL
higher	NULL
than	NULL
that	NULL
of	NULL
ATRA	NULL
.	NULL

These	NULL
data	NULL
strongly	NULL
suggest	NULL
that	NULL
ATRA	NULL
is	NULL
a	NULL
slightly	NULL
better	NULL
ligand	NULL
to	NULL
both	NULL
PML-RAR	NULL
and	NULL
RARa	NULL
than	NULL
AMS580	NULL
and	NULL
that	NULL
both	NULL
compounds	NULL
bind	NULL
better	NULL
to	NULL
the	NULL
aberrant	NULL
than	NULL
the	NULL
wild-type	NULL
receptor	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

CYTO-DIFFERENTIATING	NULL
EFFECTS	NULL
OF	NULL
AM580	NULL
ON	NULL
APL	NULL
Transactivation	NULL
potential	NULL
of	NULL
AM580	NULL
and	NULL
ATRA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RARa	NULL
and	NULL
PML-RAR	NULL
.	NULL

-	NULL
The	NULL
transactivation	NULL
potential	NULL
of	NULL
AMS580	NULL
and	NULL
ATRA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
PML-RAR	NULL
and	NULL
RARa	NULL
was	NULL
tested	NULL
on	NULL
3	NULL
different	NULL
RARE-containing	NULL
promoters	NULL
placed	NULL
in	NULL
front	NULL
of	NULL
the	NULL
bacterial	NULL
CAT	NULL
gene	NULL
used	NULL
as	NULL
a	NULL
reporter	NULL
.	NULL

The	NULL
three	NULL
promoters	NULL
contain	NULL
different	NULL
types	NULL
of	NULL
RARE	NULL
:	NULL
2	NULL
copies	NULL
of	NULL
a	NULL
palyndromic	NULL
artificial	NULL
RARE	NULL
in	NULL
the	NULL
case	NULL
of	NULL
TRE-TK	NULL
CAT	NULL
,	NULL
an	NULL
ill-defined	NULL
but	NULL
functional	NULL
RARE	NULL
in	NULL
the	NULL
case	NULL
of	NULL
LAP	NULL
CAT	NULL
,	NULL
*	NULL
and	NULL
2	NULL
copies	NULL
of	NULL
the	NULL
RAR	NULL
}	NULL
,	NULL
RARE	NULL
in	NULL
the	NULL
case	NULL
of	NULL
B	NULL
;	NULL
-RARE	NULL
CAT	NULL
.	NULL
``	NULL

Notice	NULL
that	NULL
the	NULL
LAP	NULL
promoter	NULL
is	NULL
directly	NULL
upregulated	NULL
by	NULL
ATRA	NULL
,	NULL
even	NULL
though	NULL
the	NULL
LAP	NULL
enzyme	NULL
and	NULL
the	NULL
respective	NULL
transcript	NULL
do	NULL
not	NULL
accumulate	NULL
in	NULL
NB4	NULL
cells	NULL
APL	NULL
CML	NULL
4991	NULL
py	NULL
4001	NULL
py	NULL
q	NULL
300	NULL
300	NULL
200	NULL
200	NULL
100	NULL
100	NULL
g	NULL
o	NULL
H	NULL
o	NULL
0	NULL
4000-80	NULL
-6	NULL
0	NULL
4000	NULL
B0	NULL
00-6	NULL
&	NULL
``	NULL
*j	NULL
pr	NULL
soo|	NULL
**	NULL
?	NULL

t	NULL
32	NULL
«	NULL
&	NULL
E	NULL
100	NULL
200	NULL
“	NULL
M	NULL
D	NULL
t-o	NULL
!	NULL

a	NULL
o	NULL
g	NULL
0	NULL
~100	NULL
00-80	NULL
0-6	NULL
0	NULL
1000	NULL
080	NULL
0-6	NULL
>	NULL
3	NULL
%	NULL
)	NULL
prs	NULL
soo	NULL
|	NULL
***	NULL
E3	NULL
s	NULL
B0	NULL
s	NULL
400	NULL
a	NULL
40	NULL
200	NULL
5	NULL
id	NULL
ax	NULL
o	NULL
o	NULL
!	NULL

o	NULL
-100	NULL
B0	NULL
0	NULL
4	NULL
0	NULL
1000-80	NULL
0	NULL
6	NULL
891	NULL
pra	NULL
10000	NULL
]	NULL
pr	NULL
4	NULL
so	NULL
7500	NULL
40	NULL
5000	NULL
20	NULL
$	NULL
4	NULL
2500	NULL
2	NULL
o	NULL
!	NULL

o	NULL
0	NULL
C	NULL
-00	NULL
0B	NULL
0-6	NULL
o	NULL
10	NULL
B	NULL
=	NULL
s	NULL
log	NULL
[	NULL
C	NULL
]	NULL
(	NULL
M	NULL
)	NULL
soo|	NULL
PT	NULL
S5	NULL
400	NULL
200	NULL
KM	NULL
o	NULL
!	NULL

4	NULL
0	NULL
4000	NULL
B	NULL
0	NULL
-s	NULL
log	NULL
[	NULL
C	NULL
]	NULL
(	NULL
M	NULL
)	NULL
Fig	NULL
6	NULL
.	NULL

Effects	NULL
of	NULL
AM580	NULL
and	NULL
ATRA	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
G-CSF	NULL
on	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
in	NULL
APL	NULL
blasts	NULL
and	NULL
CML	NULL
granulocytes	NULL
.	NULL

APL	NULL
blasts	NULL
(	NULL
left	NULL
panels	NULL
)	NULL
from	NULL
4	NULL
patients	NULL
or	NULL
CML	NULL
granulocytes	NULL
{	NULL
right	NULL
panels	NULL
)	NULL
from	NULL
5	NULL
patients	NULL
were	NULL
seeded	NULL
at	NULL
4	NULL
x	NULL
10°	NULL
cells/mL	NULL
and	NULL
treated	NULL
for	NULL
4	NULL
days	NULL
with	NULL
medium	NULL
,	NULL
G-CSF	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
}	NULL
,	NULL
and	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
AM58O	NULL
(	NULL
circles	NULL
)	NULL
or	NULL
ATRA	NULL
{	NULL
triangles	NULL
}	NULL
either	NULL
in	NULL
the	NULL
absence	NULL
{	NULL
open	NULL
symbols	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
solid	NULL
symbols	NULL
)	NULL
of	NULL
10	NULL
ng/mL	NULL
G-CSF	NULL
.	NULL

Cells	NULL
were	NULL
collected	NULL
and	NULL
processed	NULL
for	NULL
the	NULL
determination	NULL
of	NULL
LAP	NULL
enzymatic	NULL
activity	NULL
.	NULL

Each	NULL
experimental	NULL
value	NULL
is	NULL
the	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
three	NULL
separate	NULL
cultures	NULL
.	NULL

1527	NULL
100	NULL
HH	NULL
‘	NULL
ﬁm-ﬁ—G—ﬁ	NULL
%	NULL
positive	NULL
cells	NULL
n	NULL
~I	NULL
O	NULL
on	NULL
I	NULL
n	NULL
L	NULL
0	NULL
C400	NULL
98	NULL
96004	NULL
log	NULL
[	NULL
C	NULL
]	NULL
(	NULL
M	NULL
)	NULL
Fig	NULL
7	NULL
.	NULL

-	NULL
Effect	NULL
of	NULL
ATRA	NULL
and	NULL
AMS580	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
myeloid	NULL
surface	NULL
markers	NULL
CD11b	NULL
and	NULL
CD33	NULL
in	NULL
freshly	NULL
isolated	NULL
APL	NULL
cells	NULL
.	NULL

Leukemic	NULL
cells	NULL
(	NULL
4	NULL
x	NULL
10°/mL	NULL
)	NULL
isolated	NULL
from	NULL
1	NULL
APL	NULL
patient	NULL
(	NULL
patient	NULL
no	NULL
.	NULL

1	NULL
in	NULL
Fig	NULL
6	NULL
)	NULL
were	NULL
incubated	NULL
for	NULL
4	NULL
days	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
or	NULL
in	NULL
medium	NULL
containing	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
ATRA	NULL
(	NULL
triangles	NULL
)	NULL
or	NULL
AM5S80	NULL
(	NULL
circles	NULL
}	NULL
.	NULL

The	NULL
number	NULL
of	NULL
cells	NULL
positive	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
CD11b	NULL
(	NULL
solid	NULL
symbols	NULL
)	NULL
and	NULL
CD33	NULL
(	NULL
open	NULL
symbols	NULL
)	NULL
were	NULL
quantitated	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

For	NULL
each	NULL
experimental	NULL
point	NULL
,	NULL
appropriate	NULL
controls	NULL
consisting	NULL
of	NULL
cells	NULL
decorated	NULL
with	NULL
an	NULL
irrelevant	NULL
monoclonal	NULL
antibody	NULL
of	NULL
the	NULL
same	NULL
isotype	NULL
were	NULL
performed	NULL
.	NULL

In	NULL
these	NULL
controls	NULL
,	NULL
less	NULL
than	NULL
2	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
show	NULL
background	NULL
fluorescence	NULL
;	NULL
thus	NULL
the	NULL
results	NULL
are	NULL
not	NULL
presented	NULL
in	NULL
the	NULL
figure	NULL
.	NULL

unless	NULL
optimal	NULL
concentrations	NULL
of	NULL
G-CSF	NULL
or	NULL
cAMP	NULL
analogs	NULL
are	NULL
simultaneously	NULL
present	NULL
in	NULL
the	NULL
growth	NULL
medium	NULL
(	NULL
Fig	NULL
2	NULL
and	NULL
Sato	NULL
et	NULL
al	NULL
``	NULL
``	NULL
)	NULL
.	NULL

To	NULL
perform	NULL
these	NULL
experiments	NULL
,	NULL
COS-7	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
PML-RAR	NULL
or	NULL
RARa	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
appropriate	NULL
reporter	NULL
and	NULL
subsequently	NULL
treated	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
AMS580	NULL
or	NULL
ATRA	NULL
.	NULL

Typical	NULL
results	NULL
of	NULL
these	NULL
experiments	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
9	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
PML-RAR	NULL
(	NULL
left	NULL
panels	NULL
)	NULL
,	NULL
AMS8O	NULL
has	NULL
a	NULL
better	NULL
transactivating	NULL
potential	NULL
than	NULL
ATRA	NULL
on	NULL
the	NULL
three	NULL
reporter	NULL
genes	NULL
,	NULL
whereas	NULL
the	NULL
two	NULL
retinoids	NULL
have	NULL
similar	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RARa	NULL
(	NULL
right	NULL
panels	NULL
)	NULL
.	NULL

A	NULL
summary	NULL
of	NULL
the	NULL
results	NULL
obtained	NULL
in	NULL
several	NULL
experiments	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

If	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
EC	NULL
,	NULL
,	NULL
,	NULL
ie	NULL
,	NULL
the	NULL
concentration	NULL
of	NULL
the	NULL
retinoid	NULL
giving	NULL
half	NULL
of	NULL
the	NULL
maximal	NULL
induction	NULL
of	NULL
each	NULL
pro-moter	NULL
,	NULL
it	NULL
is	NULL
evident	NULL
that	NULL
ATRA	NULL
transactivates	NULL
each	NULL
promoter	NULL
in	NULL
a	NULL
similar	NULL
fashion	NULL
either	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PML-RAR	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RARa	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
PML-RAR	NULL
mediates	NULL
the	NULL
activity	NULL
of	NULL
AMS580	NULL
better	NULL
than	NULL
RARa	NULL
,	NULL
regardless	NULL
of	NULL
the	NULL
promoter	NULL
taken	NULL
into	NULL
consideration	NULL
.	NULL

For	NULL
LAP	NULL
CAT	NULL
,	NULL
TRE-TK	NULL
CAT	NULL
and	NULL
B	NULL
;	NULL
-RARE	NULL
CAT	NULL
,	NULL
the	NULL
transactivation	NULL
potential	NULL
of	NULL
AMS58O	NULL
is	NULL
approximately	NULL
8-	NULL
,	NULL
20-	NULL
,	NULL
and	NULL
3-fold	NULL
higher	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PML-RAR	NULL
than	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RARa	NULL
.	NULL

AMS80	NULL
selectivity	NULL
for	NULL
the	NULL
transactivation	NULL
of	NULL
PML-RAR	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1528	NULL
8000	NULL
1	NULL
_	NULL
®	NULL
6000	NULL
{	NULL
4000	NULL
{	NULL
E	NULL
d.	NULL
2000	NULL
'	NULL
A	NULL
9	NULL
£1	NULL
s	NULL
_/	NULL
g	NULL
Q	NULL
-	NULL
erea	NULL
aniratts	NULL
_	NULL
Eire	NULL
8	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
is	NULL
3000	NULL
;	NULL
Q	NULL
o	NULL
,	NULL
PML-RAR	NULL
ju	NULL
at	NULL
2	NULL
.	NULL

20004	NULL
1000	NULL
|	NULL
o	NULL
-	NULL
PCNA	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
Fraction	NULL
No	NULL
.	NULL

[	NULL
BH	NULL
]	NULL
CD	NULL
367	NULL
bound	NULL
(	NULL
%	NULL
)	NULL
GIANNI	NULL
ET	NULL
AL	NULL
log	NULL
[	NULL
ATRA	NULL
]	NULL
(	NULL
M	NULL
)	NULL
120	NULL
o	NULL
air	NULL
Bo	NULL
o	NULL
40	NULL
a	NULL
0+	NULL
-E-	NULL
r	NULL
r	NULL
B	NULL
r	NULL
,	NULL
0	NULL
-	NULL
10	NULL
0	NULL
-g	NULL
-8	NULL
-7	NULL
-6	NULL
-5	NULL
log	NULL
[	NULL
AMS80	NULL
]	NULL
(	NULL
M	NULL
)	NULL
Fig	NULL
8	NULL
.	NULL

-	NULL
Effects	NULL
of	NULL
AMS5SO	NULL
and	NULL
ATRA	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
radiolabeled	NULL
CD367	NULL
to	NULL
PML-RAR	NULL
and	NULL
RAR	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Size	NULL
exclusion	NULL
HPLC	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
COS-7	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
RARa	NULL
or	NULL
PMLRAR	NULL
expression	NULL
vectors	NULL
.	NULL

Transient	NULL
transfection	NULL
of	NULL
COS-7	NULL
cells	NULL
with	NULL
either	NULL
no	NULL
DNA	NULL
(	NULL
A	NULL
)	NULL
,	NULL
pSG5/RARa	NULL
(	NULL
®	NULL
)	NULL
,	NULL
or	NULL
PSGS/PML-RAR	NULL
(	NULL
M	NULL
)	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
calcium	NULL
phosphate	NULL
coprecipitation	NULL
method	NULL
.	NULL

Nuclear	NULL
extracts	NULL
(	NULL
200	NULL
uL	NULL
in	NULL
the	NULL
case	NULL
of	NULL
RARa	NULL
and	NULL
400	NULL
gL	NULL
in	NULL
the	NULL
case	NULL
of	NULL
PML-RAR	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
1	NULL
nmol/L	NULL
[	NULL
°H	NULL
]	NULL
CD367	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
and	NULL
O	NULL
}	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
A	NULL
)	NULL
of	NULL
a	NULL
200-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
CD367	NULL
for	NULL
18	NULL
hours	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
then	NULL
fractionated	NULL
over	NULL
a	NULL
superose	NULL
GHR	NULL
10/30	NULL
size	NULL
exclusion	NULL
column	NULL
(	NULL
Pharmacia	NULL
)	NULL
using	NULL
PTG	NULL
buffer	NULL
containing	NULL
0.4	NULL
mol/L	NULL
KCI	NULL
as	NULL
eluent	NULL
at	NULL
a	NULL
flow	NULL
rate	NULL
of	NULL
0.4	NULL
mL/min	NULL
.	NULL

RARa-bound	NULL
CD367	NULL
is	NULL
collected	NULL
in	NULL
fractions	NULL
31	NULL
through	NULL
36	NULL
,	NULL
and	NULL
PML-RAR-bound	NULL
CD367	NULL
is	NULL
collected	NULL
in	NULL
two	NULL
distinct	NULL
peaks	NULL
at	NULL
fractions	NULL
21	NULL
through	NULL
27	NULL
and	NULL
30	NULL
through	NULL
34	NULL
.	NULL

Free	NULL
CD367	NULL
is	NULL
recovered	NULL
in	NULL
fractions	NULL
43	NULL
through	NULL
47	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Competition	NULL
binding	NULL
curves	NULL
of	NULL
PH	NULL
]	NULL
CD367	NULL
with	NULL
ATRA	NULL
and	NULL
AM580	NULL
.	NULL

Nuclear	NULL
extracts	NULL
of	NULL
COS-7	NULL
cells	NULL
transfected	NULL
with	NULL
PML-RAR	NULL
(	NULL
A	NULL
)	NULL
or	NULL
RARa	NULL
(	NULL
0	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
1	NULL
nmol/L	NULL
radiolabeled	NULL
CD367	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
cold	NULL
ATRA	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
or	NULL
AM58O0	NULL
{	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

relative	NULL
to	NULL
RARa	NULL
seems	NULL
to	NULL
be	NULL
an	NULL
intrinsic	NULL
characteristic	NULL
of	NULL
this	NULL
compound	NULL
,	NULL
although	NULL
a	NULL
low	NULL
ECs	NULL
,	NULL
for	NULL
the	NULL
transactivation	NULL
of	NULL
RARE-containing	NULL
genes	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
aberrant	NULL
retinoic	NULL
acid	NULL
receptor	NULL
is	NULL
shared	NULL
by	NULL
TTNPB	NULL
and	NULL
CD367	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PML-RAR	NULL
,	NULL
TTNPB	NULL
and	NULL
CD367	NULL
transactivate	NULL
TRE-TK	NULL
CAT	NULL
,	NULL
with	NULL
ECs	NULL
,	NULL
s	NULL
of	NULL
0.4	NULL
and	NULL
0.5	NULL
x	NULL
10~°	NULL
mol/L	NULL
,	NULL
respectively	NULL
,	NULL
whereas	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RARa	NULL
,	NULL
the	NULL
two	NULL
compounds	NULL
transactivate	NULL
the	NULL
same	NULL
reporter	NULL
gene	NULL
,	NULL
with	NULL
ECs	NULL
,	NULL
s	NULL
of	NULL
0.03	NULL
and	NULL
0.3	NULL
x	NULL
107°	NULL
mol/L	NULL
,	NULL
respectively	NULL
(	NULL
re-sults	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
two	NULL
experiments	NULL
,	NULL
with	NULL
ECs	NULL
,	NULL
values	NULL
varying	NULL
less	NULL
than	NULL
20	NULL
%	NULL
between	NULL
each	NULL
other	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
TTNPB	NULL
shows	NULL
inverse	NULL
selectivity	NULL
relative	NULL
to	NULL
AMS580	NULL
,	NULL
whereas	NULL
CD367	NULL
is	NULL
a	NULL
nonselective	NULL
transactivator	NULL
of	NULL
PML-RAR	NULL
and	NULL
RARa	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
show	NULL
that	NULL
AM580	NULL
,	NULL
a	NULL
synthetic	NULL
benzoic	NULL
derivative	NULL
of	NULL
ATRA	NULL
,	NULL
originally	NULL
developed	NULL
as	NULL
a	NULL
RARa-spe-cific	NULL
agonist	NULL
,	NULL
***	NULL
``	NULL
is	NULL
considerably	NULL
more	NULL
active	NULL
than	NULL
the	NULL
natu-	NULL
ral	NULL
retinoid	NULL
in	NULL
causing	NULL
granulocytic	NULL
maturation	NULL
of	NULL
APL	NULL
cells	NULL
.	NULL

This	NULL
is	NULL
observed	NULL
on	NULL
a	NULL
series	NULL
of	NULL
differentiation	NULL
markers	NULL
that	NULL
can	NULL
be	NULL
modulated	NULL
by	NULL
retinoids	NULL
alone	NULL
or	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
these	NULL
compounds	NULL
and	NULL
other	NULL
differentiating	NULL
agents	NULL
.	NULL

Cyto-differentiation	NULL
is	NULL
observed	NULL
at	NULL
concentrations	NULL
of	NULL
AMS580	NULL
that	NULL
are	NULL
at	NULL
least	NULL
one	NULL
logarithm	NULL
lower	NULL
than	NULL
those	NULL
necessary	NULL
to	NULL
obtain	NULL
similar	NULL
results	NULL
with	NULL
ATRA	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
level	NULL
of	NULL
induction	NULL
of	NULL
a	NULL
series	NULL
of	NULL
markers	NULL
attained	NULL
at	NULL
low	NULL
concentrations	NULL
of	NULL
the	NULL
retinobenzoic	NULL
derivative	NULL
can	NULL
not	NULL
be	NULL
obtained	NULL
even	NULL
with	NULL
high	NULL
concentrations	NULL
of	NULL
ATRA	NULL
.	NULL

AMS580	NULL
shows	NULL
cosidera-ble	NULL
cell	NULL
specificity	NULL
,	NULL
because	NULL
it	NULL
is	NULL
more	NULL
active	NULL
than	NULL
ATRA	NULL
in	NULL
NB4	NULL
and	NULL
freshly	NULL
isolated	NULL
APL	NULL
promyelocytes	NULL
and	NULL
much	NULL
less	NULL
active	NULL
than	NULL
the	NULL
natural	NULL
retinoid	NULL
in	NULL
HL-60	NULL
cells	NULL
and	NULL
CML	NULL
granulocytes	NULL
.	NULL

Notably	NULL
,	NULL
ATRA	NULL
is	NULL
more	NULL
powerful	NULL
than	NULL
AMS580	NULL
in	NULL
two	NULL
other	NULL
nonhematopoietic	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
F9	NULL
teratocarcinoma	NULL
cells	NULL
,	NULL
ATRA	NULL
is	NULL
more	NULL
effective	NULL
than	NULL
AMS580	NULL
in	NULL
inducing	NULL
tissue	NULL
plasminogen	NULL
activator	NULL
and	NULL
L/B/K-type	NULL
alkaline	NULL
phos-phatase	NULL
.	NULL
``	NULL

Furthermore	NULL
,	NULL
in	NULL
L929	NULL
fibroblasts	NULL
,	NULL
when	NULL
associated	NULL
to	NULL
cAMP	NULL
analogs	NULL
,	NULL
the	NULL
natural	NULL
retinoid	NULL
is	NULL
more	NULL
powerful	NULL
than	NULL
the	NULL
synthetic	NULL
compound	NULL
in	NULL
inducing	NULL
L/B/K-type	NULL
alkaline	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

CYTO-DIFFERENTIATING	NULL
EFFECTS	NULL
OF	NULL
AM580	NULL
ON	NULL
APL	NULL
phosphatase	NULL
activity	NULL
(	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

Whereas	NULL
freshly	NULL
isolated	NULL
APL	NULL
promyelocytes	NULL
and	NULL
NB4	NULL
cells	NULL
express	NULL
PMLRAR	NULL
besides	NULL
the	NULL
normal	NULL
RARa	NULL
protein	NULL
,	NULL
CML	NULL
granulocytes	NULL
,	NULL
HL-60	NULL
,	NULL
F9	NULL
,	NULL
and	NULL
L929	NULL
cells	NULL
do	NULL
not	NULL
synthesize	NULL
PML-RAR	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
all	NULL
these	NULL
results	NULL
show	NULL
that	NULL
,	NULL
whereas	NULL
AMS580	NULL
is	NULL
an	NULL
active	NULL
retinoid	NULL
in	NULL
cells	NULL
containing	NULL
the	NULL
normal	NULL
RARa	NULL
,	NULL
the	NULL
potential	NULL
of	NULL
this	NULL
compound	NULL
is	NULL
remarkably	NULL
enhanced	NULL
in	NULL
PML-RAR-expressing	NULL
cells	NULL
.	NULL

PML-RAR	NULL
is	NULL
believed	NULL
to	NULL
have	NULL
an	NULL
important	NULL
role	NULL
in	NULL
causing	NULL
the	NULL
granulocytic	NULL
maturation	NULL
of	NULL
APL	NULL
cells	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ATRA	NULL
.	NULL
``	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
conceivable	NULL
that	NULL
the	NULL
aberrant	NULL
retinoic	NULL
acid	NULL
receptor	NULL
may	NULL
represent	NULL
the	NULL
primary	NULL
target	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
AMS80	NULL
in	NULL
APL	NULL
cells	NULL
.	NULL

Our	NULL
data	NULL
show	NULL
that	NULL
both	NULL
ATRA	NULL
and	NULL
AMS8O0	NULL
have	NULL
better	NULL
binding	NULL
affinities	NULL
for	NULL
PMLRAR	NULL
than	NULL
for	NULL
RARa	NULL
.	NULL

However	NULL
,	NULL
these	NULL
differences	NULL
in	NULL
affinity	NULL
are	NULL
small	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
Ki	NULL
of	NULL
ATRA	NULL
for	NULL
CD367	NULL
binding	NULL
to	NULL
PML-RAR	NULL
is	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
AMS8O0	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
differences	NULL
in	NULL
PML-RAR	NULL
affinity	NULL
do	NULL
not	NULL
explain	NULL
the	NULL
different	NULL
ability	NULL
of	NULL
the	NULL
two	NULL
retinoids	NULL
to	NULL
induce	NULL
granulocytic	NULL
maturation	NULL
in	NULL
APL	NULL
cells	NULL
.	NULL

We	NULL
observe	NULL
a	NULL
strong	NULL
correlation	NULL
between	NULL
the	NULL
transactivation	NULL
of	NULL
PML-RAR	NULL
by	NULL
AMS80	NULL
and	NULL
the	NULL
cyto-differentiating	NULL
effect	NULL
of	NULL
the	NULL
retinoid	NULL
on	NULL
APL	NULL
cells	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
whereas	NULL
three	NULL
different	NULL
reporter	NULL
genes	NULL
are	NULL
similarly	NULL
activated	NULL
by	NULL
ATRA	NULL
both	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RARa	NULL
and	NULL
PML-RAR	NULL
,	NULL
AMS80	NULL
activates	NULL
the	NULL
same	NULL
reporters	NULL
much	NULL
better	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
aberrant	NULL
receptor	NULL
.	NULL

Furthermore	NULL
,	NULL
AMS80	NULL
transactivates	NULL
PMLRAR	NULL
more	NULL
potently	NULL
and	NULL
at	NULL
significantly	NULL
lower	NULL
concentrations	NULL
than	NULL
ATRA	NULL
,	NULL
although	NULL
the	NULL
strength	NULL
of	NULL
the	NULL
effect	NULL
depends	NULL
on	NULL
the	NULL
reporter	NULL
taken	NULL
into	NULL
consideration	NULL
.	NULL

The	NULL
specific	NULL
interaction	NULL
between	NULL
AMS8O0	NULL
and	NULL
PML-RAR	NULL
may	NULL
,	NULL
at	NULL
least	NULL
partially	NULL
,	NULL
explain	NULL
why	NULL
this	NULL
compound	NULL
is	NULL
such	NULL
an	NULL
active	NULL
cyto-differentiating	NULL
agent	NULL
in	NULL
APL	NULL
cells	NULL
and	NULL
why	NULL
its	NULL
activity	NULL
is	NULL
superior	NULL
to	NULL
Table	NULL
1	NULL
.	NULL

Binding	NULL
Constant	NULL
and	NULL
Transactivation	NULL
Potential	NULL
of	NULL
ATRA	NULL
and	NULL
AM580	NULL
Affinity	NULL
Lap	NULL
CAT	NULL
TRE-TK	NULL
CAT	NULL
_	NULL
CAT	NULL
(	NULL
Ki	NULL
)	NULL
(	NULL
ECso	NULL
)	NULL
(	NULL
ECso	NULL
)	NULL
ATRA	NULL
PML-RAR	NULL
_	NULL
3.4	NULL
+	NULL
1.4	NULL
1.30	NULL
+	NULL
0.60	NULL
_	NULL
4.3	NULL
+	NULL
1.3	NULL
7.0	NULL
+	NULL
3.5	NULL
RARa	NULL
12.6	NULL
+	NULL
3.1*	NULL
3.80	NULL
+	NULL
1.00	NULL
_	NULL
§.5	NULL
+	NULL
1.4	NULL
9.3	NULL
+	NULL
0.9	NULL
AMS5BO	NULL
PML-RAR	NULL
15.0	NULL
+	NULL
5.2	NULL
-	NULL
0.16	NULL
+	NULL
0.05	NULL
-	NULL
0.4	NULL
+	NULL
0.1	NULL
2.8	NULL
+	NULL
1.9	NULL
RARa	NULL
32.5	NULL
+	NULL
10.8	NULL
1.30	NULL
+	NULL
0.491	NULL
7.8	NULL
+	NULL
3.1t	NULL
9.0	NULL
+	NULL
1.01	NULL
The	NULL
affinity	NULL
(	NULL
Ki	NULL
)	NULL
of	NULL
ATRA	NULL
and	NULL
AM580	NULL
for	NULL
PML-RAR	NULL
and	NULL
RARa	NULL
«	NULL
is	NULL
defined	NULL
as	NULL
the	NULL
concentration	NULL
(	NULL
in	NULL
nanomoles	NULL
)	NULL
of	NULL
each	NULL
compound	NULL
producing	NULL
50	NULL
%	NULL
displacement	NULL
in	NULL
the	NULL
[	NULL
PH	NULL
]	NULL
JCD367	NULL
binding	NULL
to	NULL
each	NULL
retinoic	NULL
acid	NULL
receptor	NULL
,	NULL
determined	NULL
as	NULL
detailed	NULL
in	NULL
the	NULL
Materials	NULL
and	NULL
Methods	NULL
from	NULL
curves	NULL
similar	NULL
to	NULL
those	NULL
shown	NULL
in	NULL
Fig	NULL
8	NULL
.	NULL

The	NULL
transactivation	NULL
potential	NULL
of	NULL
AMS8O0	NULL
and	NULL
ATRA	NULL
is	NULL
given	NULL
in	NULL
EC	NULL
;	NULL
,	NULL
ie	NULL
,	NULL
the	NULL
concentration	NULL
(	NULL
in	NULL
nanomoles	NULL
)	NULL
of	NULL
each	NULL
compound	NULL
necessary	NULL
to	NULL
produce	NULL
50	NULL
%	NULL
of	NULL
the	NULL
maximal	NULL
activation	NULL
of	NULL
each	NULL
CAT	NULL
construct	NULL
,	NULL
determined	NULL
from	NULL
plots	NULL
similar	NULL
to	NULL
those	NULL
shown	NULL
in	NULL
Fig	NULL
9	NULL
.	NULL

Each	NULL
value	NULL
is	NULL
the	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

*	NULL
Significantly	NULL
higher	NULL
(	NULL
P	NULL
<	NULL
.05	NULL
)	NULL
relative	NULL
to	NULL
the	NULL
respective	NULL
EC	NULL
;	NULL
,	NULL
value	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PML-RAR	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
the	NULL
Tukey	NULL
's	NULL
test	NULL
after	NULL
one-way	NULL
analysis	NULL
of	NULL
variance	NULL
.	NULL

t	NULL
Significantly	NULL
higher	NULL
(	NULL
P	NULL
<	NULL
.01	NULL
)	NULL
relative	NULL
to	NULL
the	NULL
respective	NULL
ECs	NULL
,	NULL
value	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PML-RAR	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
the	NULL
Tukey	NULL
's	NULL
test	NULL
after	NULL
one-way	NULL
analysis	NULL
of	NULL
variance	NULL
.	NULL

1529	NULL
PML-RAR	NULL
RARa	NULL
50	NULL
1	NULL
lap	NULL
491	NULL
lar	NULL
ao	NULL
|	NULL
5	NULL
``	NULL
CAT	NULL
30	NULL
30	NULL
10	NULL
o/	NULL
49	NULL
10	NULL
>	NULL
0	NULL
~11	NULL
-9	NULL
-7	NULL
0	NULL
411	NULL
-Q	NULL
O70	NULL
O5	NULL
Sms	NULL
``	NULL
/	NULL
5g	NULL
``	NULL
®	NULL
so|	NULL
©	NULL
c	NULL
-	NULL
so	NULL
100	NULL
4	NULL
O	NULL
40	NULL
02	NULL
)	NULL
50	NULL
E	NULL
20	NULL
1	NULL
a	NULL
o	NULL
0	NULL
4	NULL
--	NULL
--	NULL
--	NULL
--	NULL
0	NULL
o	NULL
-10	NULL
-8	NULL
-6	NULL
0	NULL
-10	NULL
-B	NULL
-6	NULL
800	NULL
1	NULL
5	NULL
,	NULL
rare	NULL
800	NULL
|	NULL
B	NULL
»	NULL
RARE	NULL
cat	NULL
cat	NULL
600	NULL
600	NULL
400	NULL
400	NULL
{	NULL
200	NULL
200	NULL
0	NULL
ﬂ	NULL
0	NULL
~	NULL
ti	NULL
0	NULL
-10	NULL
-8	NULL
-6	NULL
0	NULL
-10	NULL
-8	NULL
-6	NULL
log	NULL
{	NULL
C	NULL
]	NULL
(	NULL
M	NULL
)	NULL
log	NULL
[	NULL
C	NULL
]	NULL
(	NULL
M	NULL
)	NULL
Fig	NULL
9	NULL
.	NULL

Effects	NULL
of	NULL
AM58O	NULL
and	NULL
ATRA	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
RARE-containing	NULL
promoters	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PML-RAR	NULL
and	NULL
RARa	NULL
.	NULL

COS-7	NULL
cells	NULL
were	NULL
transiently	NULL
cotransfected	NULL
with	NULL
LAP	NULL
CAT	NULL
(	NULL
containing	NULL
the	NULL
alkaline	NULL
phosphatase	NULL
gene	NULL
upstream	NULL
promoter	NULL
)	NULL
,	NULL
TRE-TKCAT	NULL
(	NULL
containing	NULL
an	NULL
artificial	NULL
inverted	NULL
repeat	NULL
RARE	NULL
placed	NULL
in	NULL
front	NULL
of	NULL
the	NULL
viral	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
)	NULL
}	NULL
,	NULL
B	NULL
;	NULL
RARECAT	NULL
(	NULL
containing	NULL
a	NULL
natural	NULL
direct	NULL
repeat	NULL
RARE	NULL
placed	NULL
in	NULL
front	NULL
of	NULL
the	NULL
viral	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
)	NULL
,	NULL
pnisLACZ	NULL
(	NULL
containing	NULL
the	NULL
bacterial	NULL
B-galactosidase	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
a	NULL
constitutive	NULL
promoter	NULL
)	NULL
,	NULL
and	NULL
the	NULL
indicated	NULL
form	NULL
of	NULL
RAR	NULL
.	NULL

Sixteen	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
medium	NULL
was	NULL
changed	NULL
and	NULL
the	NULL
incubation	NULL
continued	NULL
for	NULL
a	NULL
further	NULL
36	NULL
hours	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
AMS580	NULL
(	NULL
@	NULL
)	NULL
or	NULL
ATRA	NULL
(	NULL
O	NULL
)	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
each	NULL
treatment	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
processed	NULL
for	NULL
the	NULL
measurement	NULL
of	NULL
CAT	NULL
and	NULL
B-galactosidase	NULL
activity	NULL
.	NULL

The	NULL
results	NULL
are	NULL
the	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
three	NULL
replicate	NULL
dishes	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
relative	NULL
CAT	NULL
activity	NULL
,	NULL
which	NULL
is	NULL
the	NULL
ratio	NULL
of	NULL
CAT	NULL
activity	NULL
produced	NULL
by	NULL
the	NULL
reporter	NULL
in	NULL
cpm	NULL
of	NULL
acetylated	NULL
chloramphenicol	NULL
divided	NULL
by	NULL
the	NULL
B-galactosidase	NULL
activity	NULL
expressed	NULL
in	NULL
absorbance	NULL
units	NULL
at	NULL
420	NULL
nm	NULL
.	NULL

that	NULL
of	NULL
ATRA	NULL
in	NULL
this	NULL
particular	NULL
leukemic	NULL
cell	NULL
type	NULL
.	NULL

Like	NULL
AMS80	NULL
,	NULL
CD367	NULL
and	NULL
TTNPB	NULL
are	NULL
much	NULL
more	NULL
powerful	NULL
than	NULL
ATRA	NULL
in	NULL
inducing	NULL
granulocytic	NULL
maturation	NULL
of	NULL
NB4	NULL
cells	NULL
.	NULL

Interestingly	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PML-RAR	NULL
,	NULL
CD367	NULL
and	NULL
TTNPB	NULL
transactivate	NULL
TRE-TK	NULL
CAT	NULL
at	NULL
concentrations	NULL
that	NULL
are	NULL
almost	NULL
identical	NULL
to	NULL
those	NULL
necessary	NULL
to	NULL
obtain	NULL
the	NULL
same	NULL
effects	NULL
with	NULL
AMS8O0	NULL
.	NULL

Thus	NULL
,	NULL
strong	NULL
interaction	NULL
with	NULL
PMLRAR	NULL
at	NULL
low	NULL
concentrations	NULL
and	NULL
potent	NULL
cyto-differentiating	NULL
activity	NULL
in	NULL
NB4	NULL
cells	NULL
are	NULL
features	NULL
common	NULL
to	NULL
AMS580	NULL
,	NULL
TTNPB	NULL
,	NULL
and	NULL
€CD367	NULL
.	NULL

Although	NULL
interaction	NULL
with	NULL
PML-RAR	NULL
may	NULL
be	NULL
the	NULL
basis	NULL
for	NULL
the	NULL
pharmacologic	NULL
activity	NULL
of	NULL
the	NULL
three	NULL
retinobenzoic	NULL
agents	NULL
in	NULL
APL	NULL
cells	NULL
,	NULL
this	NULL
does	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
other	NULL
molecular	NULL
mechanisms	NULL
have	NULL
a	NULL
role	NULL
.	NULL

With	NULL
respect	NULL
to	NULL
this	NULL
,	NULL
the	NULL
three	NULL
compounds	NULL
are	NULL
RAR	NULL
-selective	NULL
ligands	NULL
,	NULL
unlike	NULL
ATRA	NULL
and	NULL
9-cis	NULL
RA	NULL
,	NULL
which	NULL
activate	NULL
both	NULL
RARs	NULL
and	NULL
RXRs	NULL
(	NULL
the	NULL
effect	NULL
of	NULL
ATRA	NULL
on	NULL
RXRs	NULL
is	NULL
the	NULL
consequence	NULL
of	NULL
spontaneous	NULL
or	NULL
enzymatic	NULL
isomerization	NULL
to	NULL
the	NULL
9	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1530	NULL
cis	NULL
isomer	NULL
)	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
interaction	NULL
with	NULL
RXRs	NULL
may	NULL
be	NULL
of	NULL
significance	NULL
for	NULL
the	NULL
superiority	NULL
of	NULL
retinobenzoic	NULL
derivatives	NULL
on	NULL
ATRA	NULL
and	NULL
9-cis	NULL
RA	NULL
in	NULL
APL	NULL
cells	NULL
,	NULL
especially	NULL
in	NULL
consideration	NULL
of	NULL
the	NULL
fact	NULL
that	NULL
RXR	NULL
activation	NULL
does	NULL
not	NULL
seem	NULL
to	NULL
be	NULL
required	NULL
for	NULL
the	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
myeloid	NULL
cells	NULL
.	NULL
``	NULL

In	NULL
APL	NULL
cells	NULL
,	NULL
three	NULL
major	NULL
breakpoint	NULL
clusters	NULL
on	NULL
chromosome	NULL
15	NULL
(	NULL
ber-type	NULL
I	NULL
,	NULL
II	NULL
,	NULL
and	NULL
HI	NULL
)	NULL
,	NULL
which	NULL
results	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
three	NULL
distinct	NULL
types	NULL
of	NULL
PML-RAR	NULL
fusion	NULL
proteins	NULL
,	NULL
have	NULL
been	NULL
recognized	NULL
.	NULL
'	NULL

''	NULL
Although	NULL
the	NULL
number	NULL
of	NULL
cases	NULL
analyzed	NULL
is	NULL
small	NULL
,	NULL
the	NULL
selective	NULL
action	NULL
of	NULL
AMS80	NULL
on	NULL
PML-RAR	NULL
containing	NULL
APL	NULL
blast	NULL
seems	NULL
to	NULL
be	NULL
independent	NULL
of	NULL
the	NULL
type	NULL
of	NULL
aberrant	NULL
retinoic	NULL
acid	NULL
receptor	NULL
expressed	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
series	NULL
of	NULL
APL	NULL
cases	NULL
analyzed	NULL
includes	NULL
four	NULL
ber-type	NULL
I	NULL
(	NULL
NB4	NULL
cells	NULL
,	NULL
patients	NULL
no	NULL
.	NULL

2	NULL
,	NULL
3	NULL
,	NULL
and	NULL
4	NULL
)	NULL
and	NULL
one	NULL
ber-type	NULL
III	NULL
(	NULL
patient	NULL
no	NULL
.	NULL

1	NULL
)	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
chromosomal	NULL
rearrangements	NULL
.	NULL

It	NULL
would	NULL
be	NULL
important	NULL
to	NULL
establish	NULL
whether	NULL
the	NULL
three	NULL
types	NULL
of	NULL
PML-RARs	NULL
are	NULL
equally	NULL
effective	NULL
in	NULL
transactivating	NULL
RARE-containing	NULL
genes	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
AMS80	NULL
.	NULL

Similarly	NULL
,	NULL
studies	NULL
are	NULL
required	NULL
to	NULL
investigate	NULL
whether	NULL
the	NULL
retinobenzoic	NULL
analog	NULL
is	NULL
active	NULL
in	NULL
APL	NULL
relapse	NULL
cases	NULL
showing	NULL
biologic	NULL
resistance	NULL
to	NULL
ATRA	NULL
.	NULL

With	NULL
respect	NULL
to	NULL
this	NULL
last	NULL
point	NULL
,	NULL
it	NULL
is	NULL
worthwhile	NULL
mentioning	NULL
that	NULL
the	NULL
compound	NULL
is	NULL
totally	NULL
ineffective	NULL
in	NULL
inducing	NULL
granulocytic	NULL
differentiation	NULL
(	NULL
unpublished	NULL
observations	NULL
)	NULL
of	NULL
a	NULL
recently	NULL
in	NULL
vitro	NULL
developed	NULL
ATRA-resistant	NULL
NB4	NULL
clone	NULL
.	NULL
``	NULL

However	NULL
,	NULL
this	NULL
is	NULL
probably	NULL
expected	NULL
,	NULL
as	NULL
this	NULL
cell	NULL
line	NULL
does	NULL
not	NULL
express	NULL
the	NULL
PML-RAR	NULL
fusion	NULL
protein	NULL
,	NULL
``	NULL
which	NULL
seems	NULL
to	NULL
be	NULL
the	NULL
target	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
AMS580	NULL
.	NULL

Regardless	NULL
of	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
,	NULL
AMS580	NULL
is	NULL
much	NULL
more	NULL
interesting	NULL
than	NULL
CD367	NULL
and	NULL
TTNPB	NULL
from	NULL
a	NULL
perspective	NULL
therapeutical	NULL
point	NULL
of	NULL
view	NULL
.	NULL

In	NULL
vivo	NULL
,	NULL
the	NULL
retinoic	NULL
acid-mi-metic	NULL
activity	NULL
of	NULL
the	NULL
two	NULL
latter	NULL
compounds	NULL
is	NULL
very	NULL
strong	NULL
;	NULL
however	NULL
,	NULL
both	NULL
€CD367	NULL
and	NULL
TTNPB	NULL
show	NULL
significant	NULL
systemic	NULL
toxicity	NULL
``	NULL
(	NULL
unpublished	NULL
observations	NULL
)	NULL
,	NULL
probably	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
their	NULL
promiscous	NULL
ability	NULL
to	NULL
interact	NULL
with	NULL
RARa	NULL
,	NULL
,	NULL
and	NULL
y	NULL
.	NULL

The	NULL
toxicologic	NULL
profile	NULL
of	NULL
AMS580	NULL
in	NULL
animals	NULL
and	NULL
humans	NULL
is	NULL
not	NULL
yet	NULL
completely	NULL
known	NULL
,	NULL
although	NULL
it	NULL
looks	NULL
favor-able	NULL
.	NULL

This	NULL
probably	NULL
reflects	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
compound	NULL
to	NULL
significantly	NULL
interact	NULL
only	NULL
with	NULL
RARa	NULL
in	NULL
normal	NULL
animals	NULL
.	NULL

The	NULL
results	NULL
obtained	NULL
with	NULL
AMS8O0	NULL
show	NULL
that	NULL
it	NULL
is	NULL
possible	NULL
to	NULL
develop	NULL
retinoic	NULL
acid	NULL
derivatives	NULL
that	NULL
preferentially	NULL
interact	NULL
with	NULL
PML-RAR	NULL
and	NULL
are	NULL
more	NULL
effective	NULL
than	NULL
ATRA	NULL
in	NULL
causing	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
APL	NULL
cells	NULL
.	NULL

Such	NULL
compounds	NULL
may	NULL
show	NULL
lower	NULL
toxicity	NULL
and	NULL
a	NULL
higher	NULL
therapeutic	NULL
index	NULL
than	NULL
ATRA	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
this	NULL
type	NULL
of	NULL
leukemia	NULL
.	NULL

ACKNOWLEDGMENT	NULL
We	NULL
thank	NULL
Dr	NULL
M.	NULL
Lanotte	NULL
(	NULL
Unité	NULL
INSERM	NULL
301	NULL
,	NULL
``	NULL
Genetique	NULL
cellulaire	NULL
et	NULL
moleculaire	NULL
des	NULL
leucemies	NULL
``	NULL
,	NULL
Centre	NULL
G.	NULL
Hayem	NULL
,	NULL
Hopital	NULL
St	NULL
Louis	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
for	NULL
supplying	NULL
us	NULL
with	NULL
the	NULL
NB4	NULL
acute	NULL
promyelocytic	NULL
cell	NULL
line	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Dr	NULL
P.G	NULL
.	NULL

Pelicci	NULL
(	NULL
Policlinico	NULL
Monte-luce	NULL
,	NULL
Universita	NULL
di	NULL
Perugia	NULL
,	NULL
Perugia	NULL
,	NULL
Italy	NULL
)	NULL
for	NULL
the	NULL
kind	NULL
gift	NULL
of	NULL
the	NULL
plasmids	NULL
pSGS5-RARa	NULL
and	NULL
pSGS-PML-RAR	NULL
and	NULL
the	NULL
reporter	NULL
construct	NULL
TRE-TK-CAT	NULL
.	NULL

We	NULL
thank	NULL
Dr	NULL
C.	NULL
Carlberg	NULL
(	NULL
University	NULL
of	NULL
Geneva	NULL
,	NULL
Geneva	NULL
,	NULL
Switzerland	NULL
)	NULL
and	NULL
Dr	NULL
A.	NULL
Weisz	NULL
(	NULL
University	NULL
of	NULL
Naples	NULL
,	NULL
Naples	NULL
,	NULL
Italy	NULL
)	NULL
for	NULL
providing	NULL
us	NULL
with	NULL
the	NULL
reporter	NULL
construct	NULL
DR5	NULL
[	NULL
wt	NULL
]	NULL
-CAT	NULL
and	NULL
pnIlsLACZ	NULL
,	NULL
respectively	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
are	NULL
also	NULL
grateful	NULL
to	NULL
Prof	NULL
S.	NULL
Garattini	NULL
,	NULL
Dr	NULL
M.	NULL
D'Incalci	NULL
,	NULL
Dr	NULL
A.	NULL
Mantovani	NULL
,	NULL
and	NULL
Dr	NULL
M.	NULL
Salmona	NULL
for	NULL
the	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
is	NULL
GIANNI	NULL
ET	NULL
AL	NULL
dedicated	NULL
to	NULL
the	NULL
memory	NULL
of	NULL
Prof	NULL
Alfredo	NULL
Leonardi	NULL
,	NULL
the	NULL
late	NULL
Secretary	NULL
General	NULL
of	NULL
the	NULL
Istituto	NULL
di	NULL
Ricerche	NULL
Farmacologiche	NULL
``	NULL
Mario	NULL
Negri	NULL
``	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Hong	NULL
WK	NULL
,	NULL
Itri	NULL
LM	NULL
:	NULL
Retinoids	NULL
and	NULL
human	NULL
cancer	NULL
,	NULL
in	NULL
Sporn	NULL
MB	NULL
,	NULL
Roberts	NULL
AB	NULL
,	NULL
Goodman	NULL
DS	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
The	NULL
Retinoids	NULL
:	NULL
Biology	NULL
,	NULL
Chemistry	NULL
and	NULL
Medicine	NULL
(	NULL
ed	NULL
2	NULL
)	NULL
.	NULL

New	NULL
York	NULL
,	NULL
NY	NULL
,	NULL
Raven	NULL
,	NULL
1994	NULL
,	NULL
p	NULL
597	NULL
2	NULL
.	NULL

Huang	NULL
ME	NULL
,	NULL
Ye	NULL
YC	NULL
,	NULL
Chen	NULL
SR	NULL
,	NULL
Chai	NULL
JR	NULL
,	NULL
Lu	NULL
JX	NULL
,	NULL
Zhoa	NULL
L	NULL
,	NULL
Gu	NULL
LJ	NULL
,	NULL
Wang	NULL
ZY	NULL
:	NULL
Use	NULL
of	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
72:567	NULL
,	NULL
1988	NULL
3	NULL
.	NULL

Castaigne	NULL
S	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Daniel	NULL
MT	NULL
,	NULL
Ballerini	NULL
P	NULL
,	NULL
Berger	NULL
R.	NULL
Fenaux	NULL
P	NULL
,	NULL
Degos	NULL
L	NULL
:	NULL
All-trans	NULL
retinoic	NULL
acid	NULL
as	NULL
a	NULL
differentiation	NULL
therapy	NULL
for	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

I	NULL
.	NULL

Clinical	NULL
results	NULL
.	NULL

Blood	NULL
76:1704	NULL
,	NULL
1990	NULL
4	NULL
.	NULL

Breitman	NULL
TR	NULL
,	NULL
Collins	NULL
SJ	NULL
,	NULL
Keene	NULL
BR	NULL
:	NULL
Terminal	NULL
differentiation	NULL
of	NULL
human	NULL
promyelocytic	NULL
leukemic	NULL
cells	NULL
in	NULL
primary	NULL
culture	NULL
in	NULL
response	NULL
to	NULL
retinoic	NULL
acid	NULL
.	NULL

Blood	NULL
57:1000	NULL
,	NULL
1981	NULL
5	NULL
.	NULL

Larson	NULL
RA	NULL
,	NULL
Kondo	NULL
K	NULL
,	NULL
Vardiman	NULL
JW	NULL
,	NULL
Butler	NULL
AE	NULL
,	NULL
Golomb	NULL
HM	NULL
,	NULL
Rowley	NULL
JD	NULL
:	NULL
Evidence	NULL
for	NULL
a	NULL
15	NULL
;	NULL
17	NULL
translocation	NULL
in	NULL
every	NULL
patient	NULL
with	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
,	NULL
Am	NULL
J	NULL
Med	NULL
76:827	NULL
,	NULL
1984	NULL
6.	NULL
de	NULL
Thé	NULL
H	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Lanotte	NULL
M	NULL
,	NULL
Degos	NULL
L	NULL
,	NULL
Dejean	NULL
A	NULL
:	NULL
The	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
fuses	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor-alpha	NULL
gene	NULL
to	NULL
a	NULL
novel	NULL
transcribed	NULL
locus	NULL
.	NULL

Nature	NULL
347:558	NULL
,	NULL
1990	NULL
7	NULL
.	NULL

Borrow	NULL
J	NULL
,	NULL
Goddard	NULL
AD	NULL
,	NULL
Sheer	NULL
D	NULL
:	NULL
Molecular	NULL
analysis	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
breakpoint	NULL
cluster	NULL
region	NULL
on	NULL
chromosome	NULL
17	NULL
.	NULL

Science	NULL
249:1577	NULL
,	NULL
1990	NULL
8	NULL
.	NULL

Longo	NULL
L	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Rambaldi	NULL
A	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Diverio	NULL
D	NULL
,	NULL
Pegoraro	NULL
L	NULL
,	NULL
Avanzi	NULL
G	NULL
,	NULL
Tabilio	NULL
A	NULL
,	NULL
Zangrilli	NULL
D	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Donti	NULL
E	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
Rearrangements	NULL
and	NULL
aberrant	NULL
expression	NULL
of	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
gene	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
172:1571	NULL
,	NULL
1990	NULL
9	NULL
.	NULL

Pandolfi	NULL
PP	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
Structure	NULL
and	NULL
origin	NULL
of	NULL
the	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
myl/RARa	NULL
cDNA	NULL
and	NULL
characterization	NULL
of	NULL
its	NULL
retinoid-binding	NULL
and	NULL
transactivation	NULL
properties	NULL
.	NULL

Oncogene	NULL
6:1285	NULL
,	NULL
1991	NULL
10	NULL
.	NULL

Grignani	NULL
F	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Longo	NULL
L	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Donti	NULL
E	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
Acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
From	NULL
genetics	NULL
to	NULL
treatment	NULL
.	NULL

Blood	NULL
83:10	NULL
,	NULL
1994	NULL
11	NULL
.	NULL

Lanotte	NULL
M	NULL
,	NULL
Martin-Thouvenin	NULL
V	NULL
,	NULL
Najman	NULL
S	NULL
,	NULL
Ballerini	NULL
P	NULL
,	NULL
Va-lensi	NULL
F	NULL
,	NULL
Berger	NULL
R	NULL
:	NULL
NB4	NULL
,	NULL
a	NULL
maturation	NULL
inducible	NULL
cell	NULL
line	NULL
with	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
marker	NULL
isolated	NULL
from	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
M3	NULL
)	NULL
.	NULL

Blood	NULL
77:1080	NULL
,	NULL
1991	NULL
12	NULL
.	NULL

Breitman	NULL
TR	NULL
,	NULL
Selonick	NULL
SE	NULL
,	NULL
Collins	NULL
SJ	NULL
:	NULL
Induction	NULL
of	NULL
differentiation	NULL
of	NULL
the	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL-60	NULL
)	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
77:2936	NULL
,	NULL
1980	NULL
13	NULL
.	NULL

Weis	NULL
K	NULL
,	NULL
Rambaud	NULL
S	NULL
,	NULL
Lavau	NULL
C	NULL
,	NULL
Jansen	NULL
J	NULL
,	NULL
Carvalho	NULL
T	NULL
,	NULL
Carmo-Fonseca	NULL
M	NULL
,	NULL
Lamond	NULL
A	NULL
,	NULL
Dejan	NULL
A	NULL
:	NULL
Retinoic	NULL
acid	NULL
regulates	NULL
aberrant	NULL
nuclear	NULL
localization	NULL
of	NULL
PML-RARa	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
.	NULL

Cell	NULL
76:345	NULL
,	NULL
1994	NULL
14	NULL
.	NULL

Gianni	NULL
M	NULL
,	NULL
Terao	NULL
M	NULL
,	NULL
Zanotta	NULL
S	NULL
,	NULL
Barbui	NULL
T	NULL
,	NULL
Rambaldi	NULL
A	NULL
,	NULL
Garattini	NULL
E	NULL
:	NULL
Retinoic	NULL
acid	NULL
and	NULL
granulocyte-colony	NULL
stimulating	NULL
factor	NULL
syn-ergistically	NULL
induce	NULL
leukocyte	NULL
alkaline	NULL
phosphatase	NULL
in	NULL
acute	NULL
promyelocytic	NULL
lekemia	NULL
cells	NULL
.	NULL

Blood	NULL
83:1909	NULL
,	NULL
1994	NULL
15	NULL
.	NULL

Martin	NULL
B	NULL
,	NULL
Bernardon	NULL
J-M	NULL
,	NULL
Cavey	NULL
MT	NULL
,	NULL
Bernard	NULL
B	NULL
,	NULL
Carlavan	NULL
L	NULL
,	NULL
Charpentier	NULL
B	NULL
,	NULL
Pilgrim	NULL
WR	NULL
,	NULL
Shroot	NULL
B	NULL
,	NULL
Reichert	NULL
U	NULL
:	NULL
Selective	NULL
synthetic	NULL
ligands	NULL
for	NULL
human	NULL
nuclear	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

Skin	NULL
Pharmacol	NULL
5:57	NULL
,	NULL
1992	NULL
16	NULL
.	NULL

Delescluse	NULL
C	NULL
,	NULL
Cavey	NULL
MT	NULL
,	NULL
Martin	NULL
B	NULL
,	NULL
Bernard	NULL
BA	NULL
,	NULL
Reichert	NULL
U	NULL
,	NULL
Maignan	NULL
J	NULL
,	NULL
Darmon	NULL
M	NULL
,	NULL
Shroot	NULL
B	NULL
:	NULL
Selective	NULL
high	NULL
affinity	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
or	NULL
3-y	NULL
ligands	NULL
.	NULL

Mol	NULL
Pharmacol	NULL
40:556	NULL
,	NULL
1991	NULL
17	NULL
.	NULL

Graupner	NULL
G	NULL
,	NULL
Malle	NULL
G	NULL
,	NULL
Maignan	NULL
J	NULL
,	NULL
Lang	NULL
G	NULL
,	NULL
Prunieras	NULL
M	NULL
,	NULL
Pfahl	NULL
M	NULL
:	NULL
6'-substituted	NULL
naphtalene-2-carboxylic	NULL
acid	NULL
analogs	NULL
,	NULL
a	NULL
new	NULL
class	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

CYTO-DIFFERENTIATING	NULL
EFFECTS	NULL
OF	NULL
AM580	NULL
ON	NULL
APL	NULL
of	NULL
retinoic	NULL
acid	NULL
receptors	NULL
subtype-specific	NULL
ligands	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
179:1554	NULL
,	NULL
1991	NULL
18	NULL
.	NULL

Olsson	NULL
I	NULL
,	NULL
Breitman	NULL
T	NULL
,	NULL
Gallo	NULL
R	NULL
:	NULL
Priming	NULL
of	NULL
human	NULL
myeloid	NULL
leukemic	NULL
cell	NULL
lines	NULL
HL-60	NULL
and	NULL
U-937	NULL
with	NULL
retinoic	NULL
acid	NULL
for	NULL
differentiation	NULL
effects	NULL
of	NULL
cyclic	NULL
adenosine	NULL
3':5	NULL
'	NULL
monophosphate-inducing	NULL
agents	NULL
and	NULL
a	NULL
T-lymphocyte	NULL
derived	NULL
differentiation	NULL
factor	NULL
.	NULL

Cancer	NULL
Res	NULL
42:3928	NULL
,	NULL
1982	NULL
19	NULL
.	NULL

Ruchaud	NULL
S	NULL
,	NULL
Duprez	NULL
E	NULL
,	NULL
Gendron	NULL
MC	NULL
,	NULL
Houge	NULL
G	NULL
,	NULL
Genieser	NULL
HG	NULL
,	NULL
Jastorff	NULL
B	NULL
,	NULL
Doskeland	NULL
SO	NULL
,	NULL
Lanotte	NULL
M	NULL
:	NULL
Two	NULL
distinctly	NULL
regulated	NULL
events	NULL
,	NULL
priming	NULL
and	NULL
triggering	NULL
,	NULL
during	NULL
retinoid-induced	NULL
maturation	NULL
and	NULL
resistance	NULL
of	NULL
NB4	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
91:8428	NULL
,	NULL
1994	NULL
20	NULL
.	NULL

Gianni	NULL
M	NULL
,	NULL
Li	NULL
Calzi	NULL
M	NULL
,	NULL
Terao	NULL
M	NULL
,	NULL
Rambaldi	NULL
A	NULL
,	NULL
Garattini	NULL
E	NULL
:	NULL
Tyrosine	NULL
kinases	NULL
but	NULL
not	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
mediate	NULL
the	NULL
induction	NULL
of	NULL
leukocyte	NULL
alkaline	NULL
phosphatase	NULL
by	NULL
granulocyte-col-ony-stimulating	NULL
factor	NULL
and	NULL
retinoic	NULL
acid	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
208:846	NULL
,	NULL
1995	NULL
21	NULL
.	NULL

Gianni	NULL
M	NULL
,	NULL
Terao	NULL
M	NULL
,	NULL
Norio	NULL
P	NULL
,	NULL
Barbui	NULL
T	NULL
,	NULL
Rambaldi	NULL
A	NULL
,	NULL
Garattini	NULL
E	NULL
:	NULL
ATRA	NULL
and	NULL
cAMP	NULL
cooperate	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
leukocyte	NULL
alkaline	NULL
phosphatase	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
.	NULL

Blood	NULL
85:3619	NULL
,	NULL
1995	NULL
22	NULL
.	NULL

Rambaldi	NULL
A	NULL
,	NULL
Terao	NULL
M	NULL
,	NULL
Bettoni	NULL
S	NULL
,	NULL
Tini	NULL
ML	NULL
,	NULL
Bassan	NULL
R	NULL
,	NULL
Barbui	NULL
T	NULL
,	NULL
Garattini	NULL
E	NULL
:	NULL
Expression	NULL
of	NULL
leukocyte	NULL
alkaline	NULL
phosphatase	NULL
gene	NULL
in	NULL
normal	NULL
and	NULL
leukemic	NULL
cells	NULL
:	NULL
Regulation	NULL
of	NULL
the	NULL
transcript	NULL
by	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
.	NULL

Blood	NULL
762565	NULL
,	NULL
1990	NULL
23	NULL
.	NULL

Pedersen	NULL
B	NULL
:	NULL
Functional	NULL
and	NULL
biochemical	NULL
phenotype	NULL
in	NULL
relation	NULL
to	NULL
cellular	NULL
age	NULL
of	NULL
differentiated	NULL
neutrophils	NULL
in	NULL
chronic	NULL
myeloid	NULL
leukemia	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
51:339	NULL
,	NULL
1982	NULL
24	NULL
.	NULL

Sato	NULL
N	NULL
,	NULL
Asano	NULL
S	NULL
,	NULL
Urabe	NULL
A	NULL
,	NULL
Ohsawa	NULL
N	NULL
,	NULL
Takaku	NULL
F	NULL
:	NULL
Induction	NULL
of	NULL
alkaline	NULL
phosphatase	NULL
in	NULL
neutrophilic	NULL
granulocytes	NULL
,	NULL
a	NULL
marker	NULL
of	NULL
cell	NULL
maturity	NULL
,	NULL
from	NULL
bone	NULL
marrow	NULL
of	NULL
normal	NULL
individuals	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
131:1181	NULL
,	NULL
1985	NULL
25	NULL
.	NULL

Rambaldi	NULL
A	NULL
,	NULL
Terao	NULL
M	NULL
,	NULL
Bettoni	NULL
S	NULL
,	NULL
Bassan	NULL
R	NULL
,	NULL
Battista	NULL
R	NULL
,	NULL
Barbui	NULL
T	NULL
,	NULL
Garattini	NULL
E	NULL
:	NULL
Differences	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
alkaline	NULL
phosphatase	NULL
mRNA	NULL
in	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
and	NULL
paroxysmal	NULL
nocturnal	NULL
hemoglobinuria	NULL
polymorphonuclear	NULL
leukocytes	NULL
.	NULL

Blood	NULL
73:1113	NULL
,	NULL
1989	NULL
26	NULL
.	NULL

Bradford	NULL
M	NULL
:	NULL
A	NULL
rapid	NULL
and	NULL
sensitive	NULL
method	NULL
for	NULL
the	NULL
quantitation	NULL
of	NULL
microgram	NULL
quantities	NULL
of	NULL
protein	NULL
utilizing	NULL
the	NULL
principle	NULL
of	NULL
protein-dye	NULL
binding	NULL
.	NULL

Anal	NULL
Biochem	NULL
72:248	NULL
,	NULL
1976	NULL
27	NULL
.	NULL

Rambaldi	NULL
A	NULL
,	NULL
Young	NULL
DC	NULL
,	NULL
Griffin	NULL
JD	NULL
:	NULL
Expression	NULL
of	NULL
the	NULL
M-CSF	NULL
(	NULL
CSF-1	NULL
)	NULL
gene	NULL
by	NULL
human	NULL
monocytes	NULL
.	NULL

Blood	NULL
69:1409	NULL
,	NULL
1987	NULL
28	NULL
.	NULL

Weiss	NULL
MJ	NULL
,	NULL
Henthorn	NULL
PS	NULL
,	NULL
Lafferty	NULL
MA	NULL
,	NULL
Slaughter	NULL
C	NULL
,	NULL
Raducha	NULL
M	NULL
,	NULL
Harris	NULL
H	NULL
:	NULL
;	NULL
Isolation	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
cDNA	NULL
encoding	NULL
a	NULL
human	NULL
liver/bone/kidney-type	NULL
alkaline	NULL
phosphatase	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
§3:7182	NULL
,	NULL
1986	NULL
29	NULL
.	NULL

Larsen	NULL
A	NULL
,	NULL
Davis	NULL
T	NULL
,	NULL
Curtis	NULL
BM	NULL
,	NULL
Gimpel	NULL
S	NULL
,	NULL
Sims	NULL
J	NULL
,	NULL
Cosman	NULL
D	NULL
,	NULL
Park	NULL
L	NULL
,	NULL
Sorensen	NULL
E	NULL
,	NULL
March	NULL
CJ	NULL
,	NULL
Smith	NULL
C	NULL
:	NULL
Expression	NULL
cloning	NULL
of	NULL
a	NULL
human	NULL
granulocyte	NULL
colony	NULL
stimulating	NULL
factor	NULL
receptor	NULL
:	NULL
A	NULL
structural	NULL
mosaic	NULL
of	NULL
hemopoietin	NULL
receptor	NULL
immunoglobulin	NULL
and	NULL
fibronectin	NULL
do-mains	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
172:1559	NULL
,	NULL
1990	NULL
30	NULL
.	NULL

Persico	NULL
MG	NULL
,	NULL
Viglietto	NULL
G	NULL
,	NULL
Martini	NULL
G	NULL
,	NULL
Toniolo	NULL
D	NULL
,	NULL
Paonessa	NULL
G	NULL
,	NULL
Moscatelli	NULL
C	NULL
,	NULL
Dono	NULL
R	NULL
,	NULL
Vulliamy	NULL
T	NULL
,	NULL
Luzzatto	NULL
L	NULL
,	NULL
D'Urso	NULL
M	NULL
:	NULL
Isolation	NULL
of	NULL
human	NULL
glucose-6-phosphate	NULL
dehydrogenase	NULL
(	NULL
G6PD	NULL
)	NULL
cDNA	NULL
clones	NULL
:	NULL
Primary	NULL
structure	NULL
of	NULL
the	NULL
protein	NULL
and	NULL
unusual	NULL
5	NULL
'	NULL
non-coding	NULL
region	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
14:2511	NULL
,	NULL
1986	NULL
31	NULL
.	NULL

Feinberg	NULL
A	NULL
,	NULL
Vogelstein	NULL
B	NULL
:	NULL
A	NULL
technique	NULL
for	NULL
radiolabeling	NULL
DNA	NULL
restriction	NULL
endonuclease	NULL
fragments	NULL
to	NULL
high	NULL
specific	NULL
activity	NULL
.	NULL

Anal	NULL
Biochem	NULL
132:6	NULL
,	NULL
1983	NULL
32	NULL
.	NULL

Graham	NULL
FL	NULL
,	NULL
Van	NULL
Der	NULL
Eb	NULL
AJ	NULL
:	NULL
A	NULL
new	NULL
technique	NULL
for	NULL
the	NULL
assay	NULL
of	NULL
infectivity	NULL
of	NULL
human	NULL
adenovirus	NULL
5	NULL
DNA	NULL
.	NULL

Virology	NULL
52:456	NULL
,	NULL
1973	NULL
33	NULL
.	NULL

Kiledjian	NULL
M	NULL
,	NULL
Kadesch	NULL
T	NULL
:	NULL
Analysis	NULL
of	NULL
the	NULL
human	NULL
liver/bone/	NULL
kidney	NULL
alkaline	NULL
phosphatase	NULL
promoter	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
18:957	NULL
,	NULL
1990	NULL
1531	NULL
34	NULL
.	NULL

Ambrosino	NULL
C	NULL
,	NULL
Cicatiello	NULL
L	NULL
,	NULL
Cobellis	NULL
G	NULL
,	NULL
Addeo	NULL
R	NULL
,	NULL
Sica	NULL
V	NULL
,	NULL
Bresciani	NULL
F	NULL
,	NULL
Weisz	NULL
A	NULL
:	NULL
Functional	NULL
antagonism	NULL
between	NULL
the	NULL
estrogen	NULL
receptor	NULL
and	NULL
Fos	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
c-fos	NULL
protooncogene	NULL
transcrip-tion	NULL
.	NULL

Mol	NULL
Endocrinol	NULL
7:1472	NULL
,	NULL
1993	NULL
35	NULL
.	NULL

Seed	NULL
B	NULL
,	NULL
Sheen	NULL
J-Y	NULL
:	NULL
A	NULL
simple	NULL
phase-extraction	NULL
assay	NULL
for	NULL
chloramphenicol	NULL
acyltransferase	NULL
activity	NULL
.	NULL

Gene	NULL
67:271	NULL
,	NULL
1988	NULL
36	NULL
.	NULL

Cazzaniga	NULL
G	NULL
,	NULL
Seldin	NULL
MF	NULL
,	NULL
Terao	NULL
M	NULL
,	NULL
Lo	NULL
Schiavo	NULL
P	NULL
,	NULL
Galbiati	NULL
F	NULL
,	NULL
Segalla	NULL
F	NULL
,	NULL
Garattini	NULL
E	NULL
:	NULL
Isolation	NULL
,	NULL
characterization	NULL
and	NULL
chromosomal	NULL
mapping	NULL
of	NULL
the	NULL
mouse	NULL
xanthine	NULL
dehydrogenase	NULL
gene	NULL
.	NULL

Genomics	NULL
23:390	NULL
,	NULL
1994	NULL
37	NULL
.	NULL

Nervi	NULL
C	NULL
,	NULL
Poindexter	NULL
EC	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Pandolfi	NULL
,	NULL
PP	NULL
,	NULL
LoCoco	NULL
F	NULL
,	NULL
Avvisati	NULL
G	NULL
,	NULL
Pelicci	NULL
PG	NULL
,	NULL
Jetten	NULL
AM	NULL
:	NULL
Characterization	NULL
of	NULL
the	NULL
PML-RARa	NULL
chimeric	NULL
product	NULL
of	NULL
the	NULL
acute	NULL
promyelocytic	NULL
leukemia-specific	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
.	NULL

Cancer	NULL
Res	NULL
52:3687	NULL
,	NULL
1992	NULL
38	NULL
.	NULL

Rodbard	NULL
D	NULL
:	NULL
Mathematics	NULL
of	NULL
hormone-receptor	NULL
interaction	NULL
.	NULL

I	NULL
.	NULL

Basic	NULL
principles	NULL
,	NULL
in	NULL
O'Malley	NULL
BW	NULL
,	NULL
Means	NULL
AR	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Receptors	NULL
for	NULL
Reproductive	NULL
Hormones	NULL
.	NULL

New	NULL
York	NULL
,	NULL
NY	NULL
,	NULL
Plenum	NULL
,	NULL
1973	NULL
,	NULL
p	NULL
289	NULL
39	NULL
.	NULL

De	NULL
Lean	NULL
A	NULL
,	NULL
Munson	NULL
PJ	NULL
,	NULL
Rodbard	NULL
D	NULL
:	NULL
Simultaneous	NULL
analysis	NULL
of	NULL
families	NULL
of	NULL
sigmoidal	NULL
dose	NULL
curves	NULL
:	NULL
Application	NULL
to	NULL
bioassay	NULL
,	NULL
ra-dioligand	NULL
assay	NULL
,	NULL
and	NULL
physiological	NULL
dose-response	NULL
curves	NULL
.	NULL

Am	NULL
J	NULL
Phys-iol	NULL
235	NULL
:	NULL
E97	NULL
,	NULL
1978	NULL
40	NULL
.	NULL

Guiso	NULL
G	NULL
,	NULL
Rambaldi	NULL
A	NULL
,	NULL
Dimitrova	NULL
B	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Caccia	NULL
S	NULL
:	NULL
Determination	NULL
of	NULL
orally	NULL
administered	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
in	NULL
human	NULL
plasma	NULL
by	NULL
high-performance	NULL
liquid	NULL
chromatography	NULL
.	NULL

J	NULL
Chromatogr	NULL
B	NULL
656:239	NULL
,	NULL
1994	NULL
41	NULL
.	NULL

Dimitrova	NULL
B	NULL
,	NULL
Caccia	NULL
S	NULL
,	NULL
Garattini	NULL
E	NULL
,	NULL
Guiso	NULL
G	NULL
:	NULL
Determination	NULL
of	NULL
the	NULL
retinobenzoic	NULL
acid	NULL
derivative	NULL
Am580	NULL
in	NULL
rat	NULL
plasma	NULL
by	NULL
high-performance	NULL
liquid	NULL
chromatography	NULL
.	NULL

J	NULL
Chromatogr	NULL
Biomed	NULL
Appl	NULL
667:301	NULL
,	NULL
1995	NULL
42	NULL
.	NULL

Crettaz	NULL
M	NULL
,	NULL
Baron	NULL
A	NULL
,	NULL
Siegenthaler	NULL
G	NULL
,	NULL
Hunziker	NULL
W	NULL
;	NULL
Ligand	NULL
specificities	NULL
of	NULL
recombinant	NULL
retinoic	NULL
acid	NULL
receptors	NULL
and	NULL
RAR	NULL
.	NULL

Biochem	NULL
J	NULL
272:391	NULL
,	NULL
1990	NULL
43	NULL
.	NULL

Levin	NULL
AA	NULL
,	NULL
Sturzenbecker	NULL
LJ	NULL
,	NULL
Kazmer	NULL
S	NULL
,	NULL
Bosakowski	NULL
T	NULL
,	NULL
Hu-selton	NULL
C	NULL
,	NULL
Allenby	NULL
G	NULL
,	NULL
Speck	NULL
J	NULL
,	NULL
Kratzeisen	NULL
C	NULL
,	NULL
Rosenberger	NULL
M	NULL
,	NULL
Lovey	NULL
A	NULL
,	NULL
Grippo	NULL
JF	NULL
:	NULL
9-cis	NULL
retinoic	NULL
acid	NULL
stereoisomer	NULL
binds	NULL
and	NULL
activates	NULL
the	NULL
nuclear	NULL
receptor	NULL
RXRa	NULL
.	NULL

Nature	NULL
355:359	NULL
,	NULL
1992	NULL
44	NULL
.	NULL

Dermime	NULL
S	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Clerici	NULL
M	NULL
,	NULL
Nervi	NULL
C	NULL
,	NULL
Sozzi	NULL
G	NULL
,	NULL
Talamo	NULL
GP	NULL
,	NULL
Marchesi	NULL
E	NULL
,	NULL
Formelli	NULL
F	NULL
,	NULL
Parmiani	NULL
G	NULL
,	NULL
Pelicci	NULL
PG	NULL
,	NULL
Gambacorti-Passerini	NULL
C	NULL
:	NULL
Occurence	NULL
of	NULL
resistance	NULL
to	NULL
retinoic	NULL
acid	NULL
in	NULL
the	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
NB4	NULL
is	NULL
associated	NULL
with	NULL
altered	NULL
expression	NULL
of	NULL
the	NULL
pmIl/RARa	NULL
protein	NULL
.	NULL

Blood	NULL
82:1573	NULL
,	NULL
1993	NULL
45	NULL
.	NULL

Perez	NULL
A	NULL
,	NULL
Kastner	NULL
P	NULL
,	NULL
Sethi	NULL
S	NULL
,	NULL
Lutz	NULL
Y	NULL
,	NULL
Reibel	NULL
C	NULL
,	NULL
Chambon	NULL
P	NULL
;	NULL
PMLRAR	NULL
homodimers	NULL
:	NULL
Distinct	NULL
DNA	NULL
binding	NULL
properties	NULL
and	NULL
heterodimeric	NULL
interaction	NULL
with	NULL
RXR	NULL
.	NULL

EMBO	NULL
J	NULL
12:3171	NULL
,	NULL
1993	NULL
46	NULL
.	NULL

Heath	NULL
JK	NULL
,	NULL
Suva	NULL
LJ	NULL
,	NULL
Yoon	NULL
K	NULL
,	NULL
Kiledjian	NULL
M	NULL
,	NULL
Martin	NULL
TJ	NULL
,	NULL
Rodan	NULL
GA	NULL
:	NULL
Retinoic	NULL
acid	NULL
stimulates	NULL
transcriptional	NULL
activity	NULL
from	NULL
the	NULL
alkaline	NULL
phosphatase	NULL
promoter	NULL
in	NULL
the	NULL
immortalized	NULL
rat	NULL
calvarial	NULL
cell	NULL
line	NULL
,	NULL
RCT-1	NULL
.	NULL

Mol	NULL
Endocrinol	NULL
6:636	NULL
,	NULL
1992	NULL
47	NULL
.	NULL

Schrader	NULL
M	NULL
,	NULL
Wyss	NULL
A	NULL
,	NULL
Sturzenbecker	NULL
LJ	NULL
,	NULL
Grippo	NULL
JF	NULL
,	NULL
LeMotte	NULL
P	NULL
,	NULL
Carlberg	NULL
C	NULL
:	NULL
RXR-dependent	NULL
and	NULL
RXR-independent	NULL
transactivation	NULL
by	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
21:1231	NULL
,	NULL
1993	NULL
48	NULL
.	NULL

Kagechika	NULL
H	NULL
,	NULL
Kawachi	NULL
E	NULL
,	NULL
Hashimoto	NULL
Y	NULL
,	NULL
Shudo	NULL
K	NULL
:	NULL
Retinobenzoic	NULL
acids	NULL
.	NULL

2	NULL
.	NULL

Structure-activity	NULL
relationships	NULL
of	NULL
chalcone-4-carbox-ylic	NULL
acids	NULL
and	NULL
flavone-4'-carboxylic	NULL
acids	NULL
.	NULL

J	NULL
Med	NULL
Chem	NULL
32:834	NULL
,	NULL
1989	NULL
49	NULL
.	NULL

Gianni	NULL
M	NULL
,	NULL
Zanotta	NULL
S	NULL
,	NULL
Terao	NULL
M	NULL
,	NULL
Garattini	NULL
S	NULL
,	NULL
Garattini	NULL
E	NULL
:	NULL
Effects	NULL
of	NULL
synthetic	NULL
retinoids	NULL
and	NULL
retinoic	NULL
acid	NULL
isomers	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
alkaline	NULL
phosphatase	NULL
in	NULL
F9	NULL
teratocarcinoma	NULL
cells	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
196:252	NULL
,	NULL
1993	NULL
50	NULL
.	NULL

Nagy	NULL
L	NULL
,	NULL
Thomazy	NULL
VA	NULL
,	NULL
Shipley	NULL
GL	NULL
,	NULL
Fesus	NULL
L	NULL
,	NULL
Lamph	NULL
W	NULL
,	NULL
Heyman	NULL
RA	NULL
,	NULL
Chandraratna	NULL
RAS	NULL
,	NULL
Davies	NULL
PJA	NULL
:	NULL
Activation	NULL
of	NULL
retinoid	NULL
X	NULL
receptors	NULL
induces	NULL
apoptosis	NULL
in	NULL
HL-60	NULL
cell	NULL
lines	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
15:3540	NULL
,	NULL
1995	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blO	NULL
0d	NULL
1996	NULL
87	NULL
:	NULL
1520-1531	NULL
AM580	NULL
,	NULL
a	NULL
stable	NULL
benzoic	NULL
derivative	NULL
of	NULL
retinoic	NULL
acid	NULL
,	NULL
has	NULL
powerful	NULL
and	NULL
selective	NULL
cyto-differentiating	NULL
effects	NULL
on	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
A	NULL
_	NULL
48	NULL
o	NULL
6	NULL
'	NULL
t	NULL
“	NULL
f.9	NULL
'	NULL
.	NULL
'	NULL

e	NULL
>	NULL
\	NULL
/	NULL
{	NULL
®	NULL
M	NULL
Gianni	NULL
,	NULL
M	NULL
Li	NULL
Calzi	NULL
,	NULL
M	NULL
Terao	NULL
,	NULL
G	NULL
Guiso	NULL
,	NULL
S	NULL
Caccia	NULL
,	NULL
T	NULL
Barbui	NULL
,	NULL
A	NULL
Rambaldi	NULL
and	NULL
E	NULL
Garattini	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/87/4/1520.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

